<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Physiol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Physiology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28620312</article-id>
<article-id pub-id-type="pmc">5451860</article-id>
<article-id pub-id-type="doi">10.3389/fphys.2017.00352</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vallée</surname>
<given-names>Alexandre</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/350899/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Yves</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/139386/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guillevin</surname>
<given-names>Rémy</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vallée</surname>
<given-names>Jean-Noël</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Experimental and Clinical Neurosciences Laboratory, Institut National de la Santé et de la Recherche Médicale U1084, University of Poitiers</institution>
<country>Poitiers, France</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Laboratoire de Mathématiques et Applications, UMR Centre National de la Recherche Scientifique 7348, Université de Poitiers</institution>
<country>Poitiers, France</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Centre de Recherche Clinique, Hôpital de Meaux</institution>
<country>Meaux, France</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>DACTIM, Laboratoire de Mathématiques et Applications, Université de Poitiers et CHU de Poitiers, UMR Centre National de la Recherche Scientifique 7348, SP2MI</institution>
<country>Futuroscope, France</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>CHU Amiens Picardie, Université Picardie Jules Verne</institution>
<country>Amiens, France</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Angelica Merlot, University of Sydney, Australia</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Cristiana Tanase, “Victor Babes” National Institute of Pathology, Romania; Darius John Rowland Lane, University of Sydney, Australia</p>
</fn>
<corresp id="fn001">*Correspondence: Jean-Noel Vallee <email xlink:type="simple">valleejn@gmail.com</email></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>352</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>1</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Vallée, Lecarpentier, Guillevin and Vallée.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Vallée, Lecarpentier, Guillevin and Vallée</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Gliomas cells are the site of numerous metabolic and thermodynamics abnormalities with an increasing entropy rate which is characteristic of irreversible processes driven by changes in Gibbs energy, heat production, intracellular acidity, membrane potential gradient, and ionic conductance. We focus our review on the opposing interactions observed in glioma between the canonical WNT/beta-catenin pathway and PPAR gamma and their metabolic and thermodynamic implications. In gliomas, WNT/beta-catenin pathway is upregulated while PPAR gamma is downregulated. Upregulation of WNT/beta-catenin signaling induces changes in key metabolic enzyme that modify their thermodynamics behavior. This leads to activation pyruvate dehydrogenase kinase 1(PDK-1) and monocarboxylate lactate transporter 1 (MCT-1). Consequently, phosphorylation of PDK-1 inhibits pyruvate dehydrogenase complex (PDH). Thus, a large part of pyruvate cannot be converted into acetyl-CoA in mitochondria and in TCA (tricarboxylic acid) cycle. This leads to aerobic glycolysis despite the availability of oxygen, named Warburg effect. Cytoplasmic pyruvate is, in major part, converted into lactate. The WNT/beta-catenin pathway induces also the transcription of genes involved in cell proliferation, cell invasiveness, nucleotide synthesis, tumor growth, and angiogenesis, such as c-Myc, cyclin D1, PDK. In addition, in gliomas cells, PPAR gamma is downregulated, leading to a decrease in insulin sensitivity and an increase in neuroinflammation. Moreover, PPAR gamma contributes to regulate some key circadian genes. Abnormalities in the regulation of circadian rhythms and dysregulation in circadian clock genes are observed in gliomas. Circadian rhythms are dissipative structures, which play a key role in far-from-equilibrium thermodynamics through their interactions with WNT/beta-catenin pathway and PPAR gamma. In gliomas, metabolism, thermodynamics, and circadian rhythms are tightly interrelated.</p>
</abstract>
<kwd-group>
<kwd>WNT/beta-catenin pathway</kwd>
<kwd>PPAR gamma</kwd>
<kwd>gliomas</kwd>
<kwd>circadian rhythms</kwd>
<kwd>aerobic glycolysis</kwd>
<kwd>Warburg effect</kwd>
<kwd>PI3K-Akt pathway</kwd>
<kwd>lactate</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="220"></ref-count>
<page-count count="15"></page-count>
<word-count count="13027"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Gliomas are the most frequent primary brain tumors. Around 30 percent of all brain and central nervous system tumors and 80 percent of all malignant brain tumors are gliomas. They are characterized by their infiltrating nature, especially into the surrounding normal brain tissue (Goodenberger and Jenkins, <xref ref-type="bibr" rid="B57">2012</xref>). Glial cells have the potency to divide and multiply, and failure in control of this potency may result in the formation of a glioma. They contain multipotent tumor stem cells, which have the potential to be transformed into variants of normal neural progenitor cells (Galli et al., <xref ref-type="bibr" rid="B45">2004</xref>; Singh et al., <xref ref-type="bibr" rid="B173">2004</xref>). Gliomas are named on the cell type with which they share histological characteristics. They are named astrocytomas (multiform glioblastoma), oligodendrogliomas, ependymomas, and mixed gliomas (oligoastrocytomas) based on their resemblance with astrocytes, oligodendrocytes, ependymal cells, and mixed glial cells, respectively. Gliomas are classified into grade I to IV based on the criteria set by World Health Organization, with a higher-grade corresponding to more aggressive tumors. Grade I and grade II gliomas are slow-growing less aggressive tumors, whereas grade III and grade IV gliomas are malignant tumors characterized by high proliferation rate (grade III) and angiogenic activity (grade IV, Glioblastoma). Malignant gliomas are the most frequent malignant primary brain tumors (Louis, <xref ref-type="bibr" rid="B102">2006</xref>; Mamelak and Jacoby, <xref ref-type="bibr" rid="B108">2007</xref>; Ricard et al., <xref ref-type="bibr" rid="B150">2012</xref>) and the most lethal human cancers (Patil et al., <xref ref-type="bibr" rid="B131">2013</xref>). Glioblastoma patients present a median overall survival of 15 months, despite recent advances in diagnosis and therapy (Rouach et al., <xref ref-type="bibr" rid="B156">2008</xref>). Prognosis of glioblastoma is still dismal. Therefore, it is essential to investigate the mechanisms underlying the development and progression of gliomas and to explore more effective therapeutic strategies.</p>
<p>Glioma cells are the sites of numerous metabolic and thermodynamic abnormalities. They are exergonic processes in which heat flows from the tumor to their surroundings (Gillies and Gatenby, <xref ref-type="bibr" rid="B51">2015</xref>). The entropy rate increases in glioma cells and is characteristic of irreversible processes driven by changes in Gibbs energy, heat production, intracellular acidity, membrane potential gradient, and ionic conductance (Prigogine et al., <xref ref-type="bibr" rid="B140">1974</xref>; Prigogine, <xref ref-type="bibr" rid="B138">1986</xref>; Kondepudi and Prigogine, <xref ref-type="bibr" rid="B83">1999</xref>; Hanselmann and Welter, <xref ref-type="bibr" rid="B63">2016</xref>). Several cellular mechanisms can induce and develop carcinogenic processes.</p>
<p>WNT/beta-catenin signaling is a crucial factor in the development of many cancers (Leushacke and Barker, <xref ref-type="bibr" rid="B93">2012</xref>; Ramachandran et al., <xref ref-type="bibr" rid="B144">2012</xref>; Schepeler et al., <xref ref-type="bibr" rid="B165">2012</xref>). Aberrant WNT/beta-catenin signaling has a key role in the development of glioblastoma (Palos et al., <xref ref-type="bibr" rid="B127">1999</xref>), including cell proliferation (Pulvirenti et al., <xref ref-type="bibr" rid="B142">2011</xref>), cell apoptosis inhibition (Satoh and Kuroda, <xref ref-type="bibr" rid="B163">2000</xref>), and cell invasion (Roth et al., <xref ref-type="bibr" rid="B155">2000</xref>).</p>
<p>In numerous tissues, canonical WNT/beta-catenin pathway activation induces inactivation of peroxisome proliferator-activated receptor gamma (PPAR gamma), while the activation of PPAR gamma induces inhibition of canonical WNT/beta-catenin pathway (Elbrecht et al., <xref ref-type="bibr" rid="B39">1996</xref>; Fajas et al., <xref ref-type="bibr" rid="B40">1997</xref>; Wang et al., <xref ref-type="bibr" rid="B195">2008</xref>; Lecarpentier et al., <xref ref-type="bibr" rid="B87">2010</xref>; Siersbæk et al., <xref ref-type="bibr" rid="B172">2012</xref>; Zhang et al., <xref ref-type="bibr" rid="B217">2012</xref>). WNT/beta-catenin is upregulated in glioma tissues in comparison with normal brain tissues, while PPAR gamma is downregulated (Wan et al., <xref ref-type="bibr" rid="B190">2011</xref>). In glioma cells, upregulation of the WNT/beta-catenin signaling induces changes in key metabolic enzymes that modify their thermodynamics behavior. This leads to activation of pyruvate dehydrogenase kinase-1 (PDK-1) and monocarboxylate lactate transporter-1 (MCT-1) (Bienz and Clevers, <xref ref-type="bibr" rid="B8">2000</xref>; Pate et al., <xref ref-type="bibr" rid="B130">2014</xref>). Consequently, phosphorylation of PDK-1 inhibits the pyruvate dehydrogenase complex (PDH). Thus, a large part of pyruvate cannot be converted into acetyl-coenzyme A (acetyl-CoA) in mitochondria and acetyl-CoA cannot enter the tricarboxylic acid (TCA) cycle. This leads to aerobic glycolysis despite the availability of oxygen. Cytoplasmic pyruvate is, in major part, converted into lactate. This phenomenon is referred to as the Warburg effect (Warburg, <xref ref-type="bibr" rid="B196">1956</xref>). Glioblastomas present a metabolic remodeling (Tsacopoulos and Magistretti, <xref ref-type="bibr" rid="B186">1996</xref>) with an increase of both aerobic glycolysis and lactate production (Moon et al., <xref ref-type="bibr" rid="B117">2011</xref>). Increased lactate production is associated with increased aggressiveness, angiogenesis, and poor prognosis (Gruetter, <xref ref-type="bibr" rid="B60">2003</xref>; Keenan and Chi, <xref ref-type="bibr" rid="B79">2015</xref>). The WNT/beta-catenin pathway induces the transcription of genes involved in cell proliferation (c-Myc, cyclin D1, PDK). This ultimately promotes the nucleotide, protein and lipid synthesis necessary for cell growth and multiplication.</p>
<p>PPAR gamma is downregulated in glioma cells while PPAR gamma contributes to regulate some key circadian genes. Circadian rhythms (CRs) are dissipative structures, which play a key role in far-from-equilibrium thermodynamics. In gliomas, abnormalities in the regulation of CRs are observed (Fujioka et al., <xref ref-type="bibr" rid="B43">2006</xref>; Yang et al., <xref ref-type="bibr" rid="B207">2011</xref>; Li et al., <xref ref-type="bibr" rid="B94">2013</xref>). PPAR dysfunction influences statistical mechanics by modifying thermodynamic force, thermodynamic flow, and rate of entropy production (Lecarpentier et al., <xref ref-type="bibr" rid="B89">2008</xref>).</p>
<p>From a thermodynamic viewpoint and among numerous cellular processes involved in gliomas, the opposite profile of the canonical WNT/beta-catenin pathway and PPAR gamma in gliomas play a key role in both aerobic glycolysis (Warburg effect) and disruption of circadian rhythms. The thermodynamic dysregulation induced by these two processes is consubstantial with metabolic abnormalities found in glioma.</p>
<p>We focus this review on the opposing interactions observed in glioma between the canonical WNT/beta-catenin pathway and PPAR gamma and their metabolic and thermodynamic implications.</p>
</sec>
<sec id="s2">
<title>Canonical WNT/beta-catenin pathway</title>
<p>The canonical WNT/beta-catenin pathway plays an important role in metabolism, embryonic development, cell fate, and epithelial-mesenchymal transition (EMT). The canonical WNT activity is reflected by elevated levels of beta-catenin in the nucleus and/or cytoplasm, which can be detected by means of immunohistochemical staining and Western blotting. Its dysfunction is involved in numerous diseases, particularly in cancers (Moon et al., <xref ref-type="bibr" rid="B118">2002</xref>, <xref ref-type="bibr" rid="B119">2004</xref>; Nusse, <xref ref-type="bibr" rid="B124">2005</xref>; Clevers, <xref ref-type="bibr" rid="B30">2006</xref>), such as gliomas (Utsuki et al., <xref ref-type="bibr" rid="B187">2002</xref>; Sareddy et al., <xref ref-type="bibr" rid="B161">2009</xref>; Yang et al., <xref ref-type="bibr" rid="B210">2010</xref>; Liu C. et al., <xref ref-type="bibr" rid="B98">2011</xref>; Liu X. et al., <xref ref-type="bibr" rid="B101">2011</xref>; Rossi et al., <xref ref-type="bibr" rid="B154">2011</xref>; Kahlert et al., <xref ref-type="bibr" rid="B77">2012</xref>; Schule et al., <xref ref-type="bibr" rid="B167">2012</xref>; Shi et al., <xref ref-type="bibr" rid="B170">2012</xref>; Yang C. et al., <xref ref-type="bibr" rid="B204">2012</xref>; Denysenko et al., <xref ref-type="bibr" rid="B35">2016</xref>; Lee et al., <xref ref-type="bibr" rid="B92">2016</xref>). WNT pathway is a transcriptional program driven by beta-catenin/T-cell/lymphoid enhancer (TCF/LEF). The destruction complex consists of Axin, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3beta). It exerts a tightly control on the beta-catenin pathway. In the absence of WNT ligands (“off state”), the destruction complex phosphorylates beta-catenin, which is then degraded in the proteasome. In the presence of WNT ligands (“on state”), the WNT receptor interacts with Frizzled (Fzl) and LDL receptor-related protein 5/6 (LRP 5/6). WNT receptor is associated with Dishevelled (Dsh). This triggers the disruption of the destruction complex and prevents degradation of beta-catenin in the proteasome. Beta-catenin then translocates to the nucleus and interacts with TCF/LEF. This leads to the stimulation of beta-catenin target genes (PDK, MCT-1, c-Myc, cyclin D1, Cox 2, Axin2…) (He et al., <xref ref-type="bibr" rid="B66">1998</xref>; Shtutman et al., <xref ref-type="bibr" rid="B171">1999</xref>; Angers and Moon, <xref ref-type="bibr" rid="B4">2009</xref>; Pate et al., <xref ref-type="bibr" rid="B130">2014</xref>). In glioma cells, overexpression of c-Myc, a WNT target gene, promotes the Warburg effect via activation of downstream genes, such as glucose transporter (Glut), hexokinase (HK), pyruvate dehydrogenase kinase 1 (PDK1), and lactate dehydrogenase A (LDH-A) (Wang et al., <xref ref-type="bibr" rid="B192">2015</xref>). As, glucose metabolism is regulated through PI3K/Akt pathway (phosphoinositide-3-kinase protein kinase B pathway) (Wang et al., <xref ref-type="bibr" rid="B191">2016</xref>), WNT signaling has a role in glucose metabolism through PI3K/Akt pathway (Perry et al., <xref ref-type="bibr" rid="B133">2011</xref>; Cisternas et al., <xref ref-type="bibr" rid="B29">2016</xref>). WNT signaling has an important role in the control of energy intake and modulation of the energy balance (Helfer and Tups, <xref ref-type="bibr" rid="B67">2016</xref>).</p>
</sec>
<sec id="s3">
<title>PPAR gamma</title>
<p>PPAR gamma is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor super family. It heterodimerizes with retinoid X receptor (RXR). PPAR gamma is expressed in numerous cell types, such as adipose tissues, muscles, brain, and immune cells. PPAR gamma activates the expression of many genes and regulates glucose homeostasis, insulin sensitivity, lipid metabolism, immune responses, cell fate, and inflammation (Elbrecht et al., <xref ref-type="bibr" rid="B39">1996</xref>; Fajas et al., <xref ref-type="bibr" rid="B40">1997</xref>; Desvergne and Wahli, <xref ref-type="bibr" rid="B36">1999</xref>). PPAR gamma is abundantly expressed in adipose tissue and lower expressed in heart, skeletal muscle, and liver (Canevari et al., <xref ref-type="bibr" rid="B14">2004</xref>; Burkart et al., <xref ref-type="bibr" rid="B13">2007</xref>; Bright et al., <xref ref-type="bibr" rid="B12">2008</xref>). PPAR gamma is low expressed in CNS (central nervous system) and presents in several cell types such as neurons, astrocytes, oligodendrocytes, and microglia (Braissant et al., <xref ref-type="bibr" rid="B11">1996</xref>; Chiang et al., <xref ref-type="bibr" rid="B25">2010</xref>, <xref ref-type="bibr" rid="B26">2015</xref>; Chen et al., <xref ref-type="bibr" rid="B23">2012</xref>). In neurons, PPAR gamma immunoreactivity appears mainly as a nuclear labeling although sometimes cytoplasmic staining is detectable in some cortical neuron (Chiang et al., <xref ref-type="bibr" rid="B26">2015</xref>). PPAR gamma agonists thiazolidinediones (TZDs) improve insulin sensitivity in peripheral tissues (Rangwala and Lazar, <xref ref-type="bibr" rid="B145">2004</xref>) and ameliorate glucose tolerance and insulin sensitivity in type 2 diabetic patients (Picard and Auwerx, <xref ref-type="bibr" rid="B134">2002</xref>). TZDs act on the promoters of glucose transporter (GLUT2) and glucokinase (GK) in pancreatic beta-cells and liver. Abnormalities of PPAR gamma are observed in several pathological states such as cancers, diabetes, obesity, and atherosclerosis. Some TZDs have been used for treating type 2 diabetes. PPAR gamma also plays an important role in regulating cardiovascular rhythms by controlling circadian variations of blood pressure and heart rate through Bmal1 (Wang et al., <xref ref-type="bibr" rid="B195">2008</xref>; Lecarpentier et al., <xref ref-type="bibr" rid="B87">2010</xref>). PPAR gamma agonists could be regulators of glucose metabolism (Janani and Ranjitha Kumari, <xref ref-type="bibr" rid="B72">2015</xref>) given that PPAR gamma is repressed by PI3K/Akt (Berger et al., <xref ref-type="bibr" rid="B7">2015</xref>). Metabolic effects of PPAR gamma agonists are mediated by mitochondrial target of thiazolidinediones, mtot1 and mtot2 which represent the pyruvate transporter (Colca et al., <xref ref-type="bibr" rid="B32">2013</xref>). PPAR gamma agonists have potential glucose-lowering effects (Lavecchia and Di Giovanni, <xref ref-type="bibr" rid="B85">2015</xref>).</p>
</sec>
<sec id="s4">
<title>Opposing effects of the canonical WNT/beta-catenin pathway and PPAR gamma</title>
<p>The link between the WNT/beta-catenin pathway and PPAR gamma involves the TCF/LEF beta-catenin domain and a catenin binding domain within PPAR gamma. In numerous mammalian cells, PPAR gamma and WNT/beta-catenin signaling behave in an opposite manner (Gerhold et al., <xref ref-type="bibr" rid="B49">2002</xref>; Girnun et al., <xref ref-type="bibr" rid="B52">2002</xref>; Sharma et al., <xref ref-type="bibr" rid="B169">2004</xref>; Liu et al., <xref ref-type="bibr" rid="B100">2006</xref>; Takada et al., <xref ref-type="bibr" rid="B180">2009</xref>; Lu and Carson, <xref ref-type="bibr" rid="B103">2010</xref>). In some diseases, although the WNT/beta-catenin pathway is downregulated, PPAR gamma appears to be upregulated (Lecarpentier et al., <xref ref-type="bibr" rid="B88">2014</xref>). This has been observed in ARVC (Djouadi et al., <xref ref-type="bibr" rid="B37">2009</xref>), osteoporosis, bipolar disorder, and schizophrenia and certain neurodegenerative diseases (NDs) such as Alzheimer's disease (Vallée and Lecarpentier, <xref ref-type="bibr" rid="B188">2016</xref>). Conversely, in other diseases, WNT/beta-catenin signaling is upregulated while PPAR gamma is downregulated. This is the case in cancers, type 2 diabetes, and certain neurodegenerative diseases (NDs), such as amyotrophic lateral sclerosis (Lecarpentier and Vallée, <xref ref-type="bibr" rid="B86">2016</xref>), Huntington's disease, multiple sclerosis, and Friedreich's ataxia. In several cellular systems, beta-catenin is inhibited by PPAR gamma agonists (Elbrecht et al., <xref ref-type="bibr" rid="B39">1996</xref>; Fajas et al., <xref ref-type="bibr" rid="B40">1997</xref>; Moldes et al., <xref ref-type="bibr" rid="B116">2003</xref>; Zhang et al., <xref ref-type="bibr" rid="B217">2012</xref>). It has also been observed that inhibition of the WNT/beta-catenin pathway induces activation of PPAR gamma (Garcia-Gras et al., <xref ref-type="bibr" rid="B46">2006</xref>).</p>
</sec>
<sec id="s5">
<title>Activation of WNT/beta-catenin pathway and inactivation of PPAR gamma in gliomas</title>
<p>WNT/beta-catenin signaling has been activated in cancers (Polakis, <xref ref-type="bibr" rid="B135">2012a</xref>,<xref ref-type="bibr" rid="B136">b</xref>). Increased expression of beta-catenin may be due to factors such as mutations in beta-catenin, abnormalities in the beta-catenin destruction complex, mutations in APC, overexpression of WNT ligands, and loss of inhibition or decreased activity of regulatory pathways.</p>
<p>Overexpression of WNT1 and WNT3a in glioma stem cells has been shown in the malignant transformation and progression of high-grade gliomas (Zhang J. et al., <xref ref-type="bibr" rid="B216">2011</xref>; Riganti et al., <xref ref-type="bibr" rid="B152">2013</xref>; Denysenko et al., <xref ref-type="bibr" rid="B35">2016</xref>), WNT2 and WNT5 are also overexpressed in glioma. Beta-catenin is upregulated in glioblastoma tissues compared with normal brain and beta-catenin is associated with glioma progression Yu et al., <xref ref-type="bibr" rid="B212">2007</xref>; Pu et al., <xref ref-type="bibr" rid="B141">2009</xref>; Sareddy et al., <xref ref-type="bibr" rid="B161">2009</xref>; Liu C. et al., <xref ref-type="bibr" rid="B98">2011</xref>; Polakis, <xref ref-type="bibr" rid="B136">2012b</xref>. In malignant astrocytic gliomas, nuclear and nuclear-cytoplasmic positivity of beta-catenin have been shown (Utsuki et al., <xref ref-type="bibr" rid="B187">2002</xref>; Sareddy et al., <xref ref-type="bibr" rid="B161">2009</xref>; Zhang et al., <xref ref-type="bibr" rid="B220">2009</xref>; Yang et al., <xref ref-type="bibr" rid="B210">2010</xref>; Liu X. et al., <xref ref-type="bibr" rid="B101">2011</xref>; Schule et al., <xref ref-type="bibr" rid="B167">2012</xref>). In numerous studies, the nuclear translocation of beta-catenin in glioblastoma has been shown (Sareddy et al., <xref ref-type="bibr" rid="B161">2009</xref>; Yang et al., <xref ref-type="bibr" rid="B210">2010</xref>; Chen et al., <xref ref-type="bibr" rid="B21">2011</xref>; Liu C. et al., <xref ref-type="bibr" rid="B98">2011</xref>; Liu X. et al., <xref ref-type="bibr" rid="B101">2011</xref>; Zhang N. et al., <xref ref-type="bibr" rid="B218">2011</xref>; Kaur et al., <xref ref-type="bibr" rid="B78">2013</xref>; Riganti et al., <xref ref-type="bibr" rid="B152">2013</xref>). The aberrant activation of canonical WNT/beta-catenin pathway contributes to glioma development and malignant progression (Utsuki et al., <xref ref-type="bibr" rid="B187">2002</xref>; Sareddy et al., <xref ref-type="bibr" rid="B161">2009</xref>; Yang et al., <xref ref-type="bibr" rid="B210">2010</xref>; Liu X. et al., <xref ref-type="bibr" rid="B101">2011</xref>; Schule et al., <xref ref-type="bibr" rid="B167">2012</xref>; Yang C. et al., <xref ref-type="bibr" rid="B204">2012</xref>), invasion (Kahlert et al., <xref ref-type="bibr" rid="B77">2012</xref>), and prognostic implications (Liu C. et al., <xref ref-type="bibr" rid="B98">2011</xref>; Rossi et al., <xref ref-type="bibr" rid="B154">2011</xref>; Shi et al., <xref ref-type="bibr" rid="B170">2012</xref>).</p>
<p>In gliomas, PPAR gamma agonists inhibit cell proliferation by induction of cell-cycle arrest in G0/G1 phase (Zang et al., <xref ref-type="bibr" rid="B214">2003</xref>; Liu et al., <xref ref-type="bibr" rid="B99">2004</xref>; Chearwae and Bright, <xref ref-type="bibr" rid="B19">2008</xref>), and reduction of the proportion of cells entering S-phase (Zang et al., <xref ref-type="bibr" rid="B214">2003</xref>; Liu et al., <xref ref-type="bibr" rid="B99">2004</xref>; Chearwae and Bright, <xref ref-type="bibr" rid="B19">2008</xref>). PPAR gamma agonists reduce local tissue invasiveness (Grommes et al., <xref ref-type="bibr" rid="B59">2006</xref>; Papi et al., <xref ref-type="bibr" rid="B128">2009</xref>; Wan et al., <xref ref-type="bibr" rid="B190">2011</xref>), and reduce beta-catenin expression without changing its cellular localization (Wan et al., <xref ref-type="bibr" rid="B190">2011</xref>).</p>
</sec>
<sec id="s6">
<title>Aerobic glycolysis in cancer cells: role of the canonical WNT signaling (Thompson, 2014)</title>
<p>Glucose is the major source of energy for mammalian cells, including cancerous cells like gliomas. Glucose is metabolized to generate ATP, through cytosolic glycolysis and oxygen-dependent mitochondrial metabolism, in which most of the reducing potential is the outcome of the TCA cycle. The entry of glucose into the TCA cycle is controlled by PDH. Mitochondrial inactivation in cancer is predominantly due to the inhibition of PDH by PDK (Jha and Suk, <xref ref-type="bibr" rid="B74">2013</xref>).</p>
<p>The role of WNT/beta-catenin signaling in cancer development is now better understood (Bienz and Clevers, <xref ref-type="bibr" rid="B8">2000</xref>). Upregulation of the WNT/beta-catenin pathway via TCF/LEF leads to cell proliferation, EMT, migration, and angiogenesis (Brabletz et al., <xref ref-type="bibr" rid="B10">2005</xref>; Klaus and Birchmeier, <xref ref-type="bibr" rid="B81">2008</xref>; Clevers and Nusse, <xref ref-type="bibr" rid="B31">2012</xref>). In cancer cells, overactivation of the WNT/beta-catenin pathway induces aerobic glycolysis. This allows glucose utilization for cell proliferation (Pate et al., <xref ref-type="bibr" rid="B130">2014</xref>). Thus, in a large part, glucose supply is fermented to lactate regardless of oxygen availability. This phenomenon is referred to as aerobic glycolysis or the Warburg effect (Warburg, <xref ref-type="bibr" rid="B196">1956</xref>).</p>
<p>In cancer, the behavior of two key enzymes in glucose metabolism is modified leading to the Warburg effect. Activation of PDK-1 is required for the Warburg aerobic glycolysis. Upregulation of WNT/beta-catenin signaling activates both PDK-1 and MCT-1. PDK1, a major regulator of glucose metabolism, phosphorylates the PDH, which is inhibited and largely prevents the conversion of pyruvate into acetyl-CoA in mitochondria (Roche et al., <xref ref-type="bibr" rid="B153">2001</xref>). In colon cancer, PDK-1 is upregulated (Koukourakis et al., <xref ref-type="bibr" rid="B84">2006</xref>; Pate et al., <xref ref-type="bibr" rid="B130">2014</xref>), so that the conversion of pyruvate into acteyl-CoA in mitochondria is proportionally diminished with a consequent reduction of acetyl-CoA entering the tricarboxylic acid (TCA) cycle. This induces aerobic glycolysis despite the availability of oxygen. PDK-1 has also been observed to be upregulated in several other cancers (Wigfield et al., <xref ref-type="bibr" rid="B197">2006</xref>; Baumunk et al., <xref ref-type="bibr" rid="B5">2013</xref>). Cytosolic pyruvate is converted into lactate through activation of LDH-A. Upregluation of both lactic dehydrogenase-A (LDH-A) and lactate transporter (MCT-1) results in pyruvate being diverted toward the formation of lactate and the secretion of the latter outside of the cell, which favors angiogenesis (Hunt et al., <xref ref-type="bibr" rid="B71">2007</xref>) and ultimately leads to anabolic production of biomass, nucleotide synthesis (De Berardinis et al., <xref ref-type="bibr" rid="B34">2008</xref>; Vander Heiden et al., <xref ref-type="bibr" rid="B189">2009</xref>). The Warburg effect partly shunts the TCA cycle leading to aerobic glycolysis, which is less efficient in terms of ATP production. The most cost effective way production ATP is via glucose oxidation (ATP/O<sub>2</sub> = 6.4), since the pathway via free fatty acid beta-oxidation is less efficient (ATP/O<sub>2</sub> = 5.6). This takes about 11% more O2 to produce the same amount of ATP from fatty acids as it does from glucose. Moreover, PDK-1 and 2 enhance angiogenesis (McFate et al., <xref ref-type="bibr" rid="B112">2008</xref>; Sutendra et al., <xref ref-type="bibr" rid="B178">2013</xref>). Blocking WNT reduces the PDK-1 level via the transcription regulation and reduces <italic>in vivo</italic> tumor growth. Conversely, PPAR gamma activation selectively decreases PDK mRNA (Abbot et al., <xref ref-type="bibr" rid="B1">2005</xref>). PDKs allow metabolic flexibility (Zhang et al., <xref ref-type="bibr" rid="B219">2014</xref>) and are transcriptionally regulated by insulin, glucocorticoids, thyroid hormone and fatty acids (Lee, <xref ref-type="bibr" rid="B91">2014</xref>). Several diseases presenting PDK abnormalities are often associated with type 2 diabetes, obesity, metabolic disorders, cardiomyoptahies, neuropathies, and cancers.</p>
<p>In colon cancer, activation of WNT/beta-catenin signaling proportionally decreases the oxidative metabolism in the TCA cycle and promotes cell proliferation (Pate et al., <xref ref-type="bibr" rid="B130">2014</xref>). In addition, the WNT/beta-catenin pathway induces the transcription of genes involved in cell proliferation, particularly cyclin D1 and c-Myc operating through the G1 phase (Osthus et al., <xref ref-type="bibr" rid="B125">2000</xref>; Nusse, <xref ref-type="bibr" rid="B124">2005</xref>; Niehrs and Acebron, <xref ref-type="bibr" rid="B123">2012</xref>). c-Myc activates aerobic glycolysis and glutaminolysis and favors nucleotide synthesis (Wise et al., <xref ref-type="bibr" rid="B199">2008</xref>). Moreover, c-Myc increases the hypoxia-inducible factor 1 alpha (HIF-1 alpha) with controls PDK-1 (Kim et al., <xref ref-type="bibr" rid="B80">2007</xref>). Part of the pyruvate entering the TCA cycle is converted into citrate, which promotes protein and lipid synthesis. Cellular accumulation of metabolic intermediates (aspartate, serine, glycine, and ribose) allows <italic>de novo</italic> nucleotide synthesis, which contributes to growth and proliferation. Angiogenesis is also favored by production of lactate (Lu et al., <xref ref-type="bibr" rid="B104">2002</xref>).</p>
<p>Phosphofructokinase (PFK), an allosteric enzyme, is responsible for glycolytic oscillations. PFK can lead to instabilities beyond which a new state can be organized in time and in space (Goldbeter, <xref ref-type="bibr" rid="B54">1973</xref>). A positive feedback is responsible for periodic behavior. These far-from-equilibrium oscillatory mechanisms come within the field of dissipative structures initially described by Prigogine (Prigogine and Nicolis, <xref ref-type="bibr" rid="B139">1971</xref>). Elevated PFK-1 activity is characteristic of cancer cells and is induced in response to ontogenesis (Mor et al., <xref ref-type="bibr" rid="B120">2011</xref>).</p>
</sec>
<sec id="s7">
<title>Canonical WNT pathway and glucose</title>
<p>Cancer cells are characterized by increased glucose consumption. High serum glucose levels may modulate cancer-related processes. Glucose itself can directly impact the canonical WNT pathway (Chocarro-Calvo et al., <xref ref-type="bibr" rid="B28">2013</xref>). High glucose level enhances the nuclear translocation of beta-catenin in response to WNT activation. In cancer cells, glucose-induced beta-catenin acetylating favors the WNT pathway.</p>
</sec>
<sec id="s8">
<title>Aerobic glycolysis in gliomas (cf. Figure <xref ref-type="fig" rid="F1">1</xref>)</title>
<p>Glucose metabolism has been identified as important biological markers in glioma cells for the progression of gliomas (Morfouace et al., <xref ref-type="bibr" rid="B121">2012</xref>). Glycolytic metabolism is upregulated in gliomas (Mineura et al., <xref ref-type="bibr" rid="B115">1986</xref>; Oudard et al., <xref ref-type="bibr" rid="B126">1996</xref>). Activation of PDK in gliomas leads to shunt pyruvate from the mitochondria (Jha and Suk, <xref ref-type="bibr" rid="B74">2013</xref>). Glioma cells suffer from nutrient deprivation and are more susceptible to cytotoxic killing than normal astrocytes (Spagnolo et al., <xref ref-type="bibr" rid="B175">2007</xref>). This effect is mediated by reactive oxygen species produced by mitochondria (Ahmad et al., <xref ref-type="bibr" rid="B2">2005</xref>). Numerous studies on gliomas have shown the dependence of glioma cells on glycolysis as primary source of energy (Maurer et al., <xref ref-type="bibr" rid="B110">2011</xref>). Upregulation of glycolysis shows increasing glucose consumption and is defined as a feature of primary and metastatic cancers (Gatenby and Gillies, <xref ref-type="bibr" rid="B47">2004</xref>). High-grade gliomas have high rates of glycolysis and lactate production (Jha and Suk, <xref ref-type="bibr" rid="B74">2013</xref>). Overexpression of MCTs, especially MCT-1, has been reported in neoplasic human cells, including the most aggressive forms of glioma cells tumors (Galeffi and Turner, <xref ref-type="bibr" rid="B44">2012</xref>). MCT-1 immunoreactivity is significantly higher in high-grade glioma than low-grade (Froberg et al., <xref ref-type="bibr" rid="B41">2001</xref>). The overexpression of MCTs is likely an adaptive response of tumor expansion at different levels. It helps glioma cells to maintain a high rate of glycolysis by exporting lactate to extracellular space. Glioma cells have an increase of lactate concentration in intracellular, which are accompanied by a progressive inhibition of the TCA cycle (Bouzier-Sore et al., <xref ref-type="bibr" rid="B9">2001</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Role of WNT/beta-catenin pathway on aerobic glycolysis in gliomas. In the presence of WNT ligands (“on state”), WNT binds both Frizzled and LRP 5/6 receptors to initiate LRP phosphorylation of the Axin/APC/GSK-3beta complex. Beta-catenin phosphorylation is inhibited which prevents its degradation in the proteasome. Beta-catenin accumulates in the cytosol and then translocates to the nucleus to bind TCF-LEF co transcription factors. This induces the WNT-response gene transcription (PDK, c-Myc, cyclin D, MCT-1). Glucose itself activates the WNT pathway. MCT-1 favors lactate extrusion out of the cytosol which favors angiogenesis. WNT/beta-catenin pathway stimulates tyrosine kinase receptors (TKRs) activation. Activation of PI3K/Akt increases glucose metabolism. Akt-transformed cells protect against reactive oxygen species stress (ROS stress) by inducing HIF-1alpha, which suppresses glucose entry into the TCA cycle. HIF-1alpha induced PDK1 phosphorylates PDH, which resulting in cytosolic pyruvate being shunted into lactate through induction of LDH-A. PDK inhibits the PDH complex in mitochondria, thus pyruvate cannot be fully converted into acetyl-CoA and enter the TCA cycle. c-Myc and cyclin D also activates LDH-A which converts cytosolic pyruvate into lactate. c-Myc increases glutamine entry in the cytosol and mitochondria. c-Myc-induced glutamine enhances aspartate and nucleotide synthesis.</p>
</caption>
<graphic xlink:href="fphys-08-00352-g0001"></graphic>
</fig>
</sec>
<sec id="s9">
<title>Role of PI3K-Akt pathway in aerobic glycolysis in gliomas (cf. Figure <xref ref-type="fig" rid="F1">1</xref>)</title>
<p>EGFR (Epidermal growth factor receptor) is a type of receptor tyrosine kinase (RTK) playing a central role in cell division, migration, adhesion, differentiation, and apoptosis (Chakravarti et al., <xref ref-type="bibr" rid="B18">2004</xref>; Mellinghoff et al., <xref ref-type="bibr" rid="B113">2005</xref>). EGFR overexpression, occurring in 30–70% of primary glioblastomas is the most frequent mutation (Popescu et al., <xref ref-type="bibr" rid="B137">2016</xref>). EGFR activation by binding PI3K (phosphoinositide-3-kinase), Akt (protein kinase B), STAT (signal transducer and activator of transcription) etc. modulates cell proliferation, differentiation and survival (Park et al., <xref ref-type="bibr" rid="B129">2004</xref>; Seshacharyulu et al., <xref ref-type="bibr" rid="B168">2012</xref>). WNT/beta-catenin pathway stimulates tyrosine kinase receptors (TKRs) activation in gliomas (Gruetter, <xref ref-type="bibr" rid="B60">2003</xref>; Yang et al., <xref ref-type="bibr" rid="B206">2016</xref>). Downregulation of beta-catenin reduces the expression of EGFR, Akt1, Akt2, and phosphorylates Akt (Park et al., <xref ref-type="bibr" rid="B129">2004</xref>; Yue et al., <xref ref-type="bibr" rid="B213">2010</xref>; Zhang N. et al., <xref ref-type="bibr" rid="B218">2011</xref>).</p>
<p>EGFR activates PI3K. PIP2 (phosphatidylinositol-3,4-biphosphate) is converted in PIP3 (phosphosphatidyk-3,4,5-triphosphates) by PI3K and back by phosphatase and tensin homolog (PTEN) (Yue et al., <xref ref-type="bibr" rid="B213">2010</xref>; Sami and Karsy, <xref ref-type="bibr" rid="B159">2013</xref>). PI3K activates Akt signaling while PTEN suppresses it, Akt is activated by phosphorylation. Increasing Akt signaling inactivates GSK-3beta by phosphorylating the protein at Ser-9, this leads to nuclear translocation and stabilization of beta-catenin (Paw et al., <xref ref-type="bibr" rid="B132">2015</xref>). PI3K/Akt signaling pathway is involved in cell proliferation, cell survival, and endothelial cell migration (Sami and Karsy, <xref ref-type="bibr" rid="B159">2013</xref>; Xu et al., <xref ref-type="bibr" rid="B203">2013</xref>; Wang et al., <xref ref-type="bibr" rid="B194">2014</xref>). PI3K/Akt pathway regulates beta-catenin stability, localization, transcriptional activity (Paw et al., <xref ref-type="bibr" rid="B132">2015</xref>), and the expression of its downstream genes (such as cyclin D1, c-Myc) (Ji et al., <xref ref-type="bibr" rid="B75">2011</xref>).</p>
<p>Activation of PI3K/Akt increases glucose metabolism. Hyper activation of PI3K/Akt pathway is associated with an increased rate of glucose metabolism in tumor cells (Reuter et al., <xref ref-type="bibr" rid="B148">2010</xref>). Akt signaling directly acts on glycolysis in cancer cells. Akt regulates the localization of GLUT1 in the plasma membrane and hexokinase expression. It also activates phosphofructokinase-1 (PFK-1), which directly phosphorylates PFK2, leading to the production of fructose-2,6-biphosphate, an activator of PFK1. Akt activation causes an increase in aerobic glycolysis effect in cancer. PI3K/Akt pathway promotes cell survival, cell growth, cell proliferation, cell migration and angiogenesis in response to extracellular signals including hormones and growth factors. Through phosphorylation of GSK-3beta, PI3K/Akt favors the G1-S phase of the cell cycle. GSK-3beta phosphorylation decreases the degradation of beta-catenin in the proteasome. Thus, TCF/LEF transcription factor is activated, which in turn favors transcription of the target gene cyclin D1 (Alao, <xref ref-type="bibr" rid="B3">2007</xref>). PI3K/Akt contributes to angiogenesis by acting on the vascular endothelial growth factor in endothelial cells and on the endothelial nitric oxide synthase; this activates vasodilatation and vascular remodeling (Manning and Cantley, <xref ref-type="bibr" rid="B109">2007</xref>).</p>
<p>Akt-transformed cells protect against reactive oxygen species stress (ROS stress) by inducing HIF-1alpha, which suppresses glucose entry into the TCA cycle (Lum et al., <xref ref-type="bibr" rid="B105">2007</xref>). HIF-1alpha induced PDK1 (pyruvate dehydrogenase kinase 1) phosphorylates PDH (pyruvate dehydrogenase), which resulting in cytosolic pyruvate being shunted into lactate through induction of LDH-A (lactate dehydrogenase A) (Suda et al., <xref ref-type="bibr" rid="B176">2011</xref>). Activation of PI3K/Akt results in aerobic glycolysis. Blockage of EGFR/PI3K/Akt signaling axe could be an interesting therapeutic perspective to improve the survival of patients with glioblastoma (Tanase et al., <xref ref-type="bibr" rid="B182">2013</xref>).</p>
</sec>
<sec id="s10">
<title>Prostaglandins, WNT/beta-catenin pathway, and PPAR gamma in gliomas</title>
<p>Several studies have established the role of prostaglandin E2 (PGE2) by activating the WNT/beta-catenin pathway. The link between PGE2 and the canonical WNT pathway suggests that chronic inflammation induced by a prolonged increase of PGE2 could lead to activation of WNT signaling resulting in cell proliferation and cancer. PGE2 enhances the beta-catenin-dependent transcription (Castellone et al., <xref ref-type="bibr" rid="B17">2005</xref>; Suda et al., <xref ref-type="bibr" rid="B176">2011</xref>). PGE2 could promote cancer cells growth through the beta-catenin pathway. Thus, blockage of WNT/beta-catenin signaling can be of interest for gliomas treatment.</p>
<p>NSAIDs (non-steroidal anti-inflammatory drugs) can reduce nuclear beta-catenin levels and induce beta-catenin degradation (Rice et al., <xref ref-type="bibr" rid="B151">2003</xref>; Tinsley et al., <xref ref-type="bibr" rid="B185">2011</xref>; Gurpinar et al., <xref ref-type="bibr" rid="B62">2014</xref>). Sulindac, exisulind, and celecoxib (NSAIDs) decrease beta-catenin level and inhibit transcriptional activity of the beta-catenin/TCF/LEF complex (Thompson et al., <xref ref-type="bibr" rid="B184">2000</xref>; Maier et al., <xref ref-type="bibr" rid="B107">2005</xref>). NSAIDs inhibit glioma invasion <italic>in vitro</italic> by dephosphorylation of Akt, which causes a decrease in MMP-2 gene expression and activity (Lee et al., <xref ref-type="bibr" rid="B90">2005</xref>; Paw et al., <xref ref-type="bibr" rid="B132">2015</xref>). NSAIDs can eliminate stem cells with nuclear beta-catenin and aberrant WNT signaling in APC Min mice and in human colonic polyps through the induction of apoptosis (Jiang et al., <xref ref-type="bibr" rid="B76">2012</xref>). Ibuprofen (which belong to the group of NSAIDs) have significant effects on glioma cell proliferation and apoptosis (Ribeiro et al., <xref ref-type="bibr" rid="B149">2008</xref>; Benadiba et al., <xref ref-type="bibr" rid="B6">2010</xref>), PGE2 alters proliferative, apoptotic and migratory, and migratory properties of human glioma cells (Gomes and Colquhoun, <xref ref-type="bibr" rid="B56">2012</xref>).</p>
<p>PGE2 modulates WNT activity hematopoietic stem cell (HSC) in zebrafish. Inhibition of PGE2 synthesis blocks alterations in HSC induced by WNT. PGE2 modifies the WNT signaling cascade at the level of beta-catenin degradation through the cAMP/PKA pathway. WNT activation in stem cells requires PGE2 (Goessling et al., <xref ref-type="bibr" rid="B53">2009</xref>). Dimethyl-prostaglandin E2 increases HSC <italic>in vivo</italic>. In addition, dimethyl-prostaglandin E2 leads to the formation of components of the WNT pathway (Li et al., <xref ref-type="bibr" rid="B95">2014</xref>). WNT signaling upregulates interleukin (IL)-7R and IL-2Rbeta. In neuroectodermal (NEC-4C) stem cells, PGE2 interacts with canonical WNT signaling through PKA and PI3K (Wong et al., <xref ref-type="bibr" rid="B200">2014</xref>). In WNT-induced cells, beta-catenin is increased and the WNT-targets gens (Ctnnb1, Ptgs2, Ccnd1, Mmp9) are significantly upregulated after PGE2 used. COX-2/PGE2 have a functional role in glioma (Chiu et al., <xref ref-type="bibr" rid="B27">2010</xref>). Specific COX-2 inhibitor inhibited the proliferation and invasion of cultured glioma cell lines. PPAR gamma and pro-inflammatory enzyme pathways are interrelated. Decreased expression of PPAR gamma and high levels of cyclooxygenase-2 (COX-2) have been reported in many cancers (Hazra et al., <xref ref-type="bibr" rid="B65">2008</xref>). TZDs decrease COX-2, inhibit growth of non-small-cell lung cancer cells <italic>in vitro</italic>, and block tumor development. TZDs diminish COX-2and PGE2 through PPAR gamma. The PPAR gamma activator 15dPGJ2 pays an anti-inflammatory role in PPAR gamma-dependent manner, decreasing COX-2, PGE2, and iNOs expression (Mendez and LaPointe, <xref ref-type="bibr" rid="B114">2003</xref>).</p>
</sec>
<sec id="s11">
<title>Circadian rhythms (CRs), gliomas, metabolism, and thermodynamics (cf. Figure <xref ref-type="fig" rid="F2">2</xref>) (Savvidis and Koutsilieris, 2012)</title>
<p>The circadian “clock,” located in the hypothalamic suprachiasmatic nucleus (SCN), is known to drive numerous biologic processes in the body. CRs can be defined as endogenous, entrainable free-running periods that last ~24 h. CRS are far-from-equilibrium dissipative structures and are due to a negative feedback produced by a protein on the expression of its own gene (Goodwin, <xref ref-type="bibr" rid="B58">1965</xref>; Hardin et al., <xref ref-type="bibr" rid="B64">1990</xref>). They operate in far-from-equilibrium manner if affinity of the studied system is RT (R is the universal gas constant and T is the absolute temperature), and generate order spontaneously by exchanging energy with their external environment (Prigogine et al., <xref ref-type="bibr" rid="B140">1974</xref>; Goldbeter, <xref ref-type="bibr" rid="B55">2002</xref>). In mammals, CRs involve several major critical transcription factors Clock (Circadian locomotors output cycles kaput), Bmal1 (brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1), Per1 (Period 1), Per2 (Period 2), Per3 (Period 3), Cryptochrome (Cry 1 and Cry 2) (Gekakis et al., <xref ref-type="bibr" rid="B48">1998</xref>; Hogenesch et al., <xref ref-type="bibr" rid="B69">1998</xref>). Transcription/translation auto regulatory feedback loops with both activating and inhibiting pathways are involved in CRs (Reppert and Weaver, <xref ref-type="bibr" rid="B147">2002</xref>; Schibler and Sassone-Corsi, <xref ref-type="bibr" rid="B166">2002</xref>). Clock and Bmal1 heterodimerize and initiate transcription of target genes, such as Period (Per1 and Per2) and Cryptochrome (Cry1 and Cry2) (Ko and Takahashi, <xref ref-type="bibr" rid="B82">2006</xref>). A negative feedback is achieved by Per/Cry heterodimers that translocate back to the nucleus to repress their own transcription by acting on the Clock/Bmal1 complex (Ko and Takahashi, <xref ref-type="bibr" rid="B82">2006</xref>). Clock/Bmal1 heterodimers activate transcription of retinoic acid-related orphan nuclear receptors, such as Rev-Erbs and RORs (retinoic acid receptor-related orphan receptors). In feedback, RORs activate transcription of Bmal1, whereas Rev-Erbs repress the transcription process (Ko and Takahashi, <xref ref-type="bibr" rid="B82">2006</xref>). RORs are regulation factors downstream of the WNT/beta-catenin pathway (Chen, <xref ref-type="bibr" rid="B22">2004</xref>). The circadian oscillation of Bmal1 is both positively and negatively regulated by RORs and Rev-Erbs.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Opposing effects of PPAR gamma and canonical WNT/beta-catenin signaling in gliomas. Circadian rhythms disorders are observed in Gliomas, with decreasing of Per and increasing of Bmal1 and Clock. Overexpression of Bmal1 induces activation of WNT pathway. Upregulation of canonical WNT and downregulation of PPAR gamma are observed in gliomas. PI3K/Akt pathway and PGE2 also activate beta-catenin. The activation of beta-catenin induces transcription of WNT targets genes such as PDK, MCT-1, c-Myc, and cyclin D. PDK inhibits the PDH complex in mitochondria, thus pyruvate cannot be fully converted into acetyl-CoA and enter the TCA cycle. c-Myc and cyclin D activates LDH-A which converts cytosolic pyruvate into lactate. MCT-1 favors lactate extrusion out of the cytosol which favors angiogenesis. This effect is called aerobic glycolysis. Activation of WNT/beta-catenin pathway induces aerobic glycolysis, and then results in cell proliferation, nucleotide synthesis, protein synthesis and angiogenesis in gliomas. PPAR gamma agonists induce activation of Bmal1 and the formation of heterodimers Clock/Bmal1, and then inhibit the WNT pathway. PPAR gamma agonists directly inhibit activation of beta-catenin and its nuclear translocation and then inhibit transcription of WNT targets genes. Using PPAR gamma agonists may interest to stop gliomas progression through inhibition of aerobic glycolysis via inactivation of canonical WNT/beta-catenin pathway.</p>
</caption>
<graphic xlink:href="fphys-08-00352-g0002"></graphic>
</fig>
<p>CRs govern numerous physiological and metabolic functions (Sahar and Sassone-Corsi, <xref ref-type="bibr" rid="B157">2009</xref>). Thus, CRs are observed in sleep-awake and feeding patterns, energy metabolism, body temperature, hormone secretion, heart rate, and blood pressure. Following epidemiological and genetic probes, it has been suggested that disruption of CRs may be directly linked to cancer, leading to aberrant cellular proliferation (Wood et al., <xref ref-type="bibr" rid="B201">2009</xref>). Since numerous connections between the circadian clock and cellular metabolism have been reported, it is through that the abnormal metabolism observed in cancer may be a consequence of disrupted CRs. Altered links between the circadian clock and cellular metabolism have been discovered and might be regulated by chromatin remodeling. CRs within the cell regulate the timing of many important life cycles (Cao et al., <xref ref-type="bibr" rid="B16">2015</xref>). The phase diffusion constant depends on the free-energy dissipation per period. Oscillations are driven by multiple irreversible cycles that hydrolyze fuel molecules such as ATP. The free energy consumed per period is proportional to the number of phase coherent periods.</p>
<p>Circadian genes may control cell cycle progression via WNT pathway which contains putative Bmal1/clock-binding sites within its promoters (WNT10a, beta-catenin, Dsh2, TCF3) (Soták et al., <xref ref-type="bibr" rid="B174">2014</xref>). A Bmal1 knockdown inhibits WNT signaling expression and activity (Guo et al., <xref ref-type="bibr" rid="B61">2012</xref>). Lower levels of WNT-related genes are associated with Bmal1 knockdown compared to the expression of WNT-related genes factors varies with a 12-h period in wild-type mice (Janich et al., <xref ref-type="bibr" rid="B73">2011</xref>). Bmal1 knockout mice show lower levels of WNT-related genes (Yasuniwa et al., <xref ref-type="bibr" rid="B211">2010</xref>). Circadian disruption accelerates tumor growth through the WNT pathway in nude mouse xenograft models (Reppert and Weaver, <xref ref-type="bibr" rid="B147">2002</xref>). Cell proliferation and cell cycle progression may regulate by circadian clock gene Bmal1 through activation of canonical WNT/beta-catenin pathway (Lin et al., <xref ref-type="bibr" rid="B96">2013</xref>). Bmal1 may reduce beta-catenin degradation and may enhance its transcription. Bmal1 represses WNT inhibitors or degradation factors of beta-catenin, like GSK-3beta (Coyle, <xref ref-type="bibr" rid="B33">2007</xref>; Sahar et al., <xref ref-type="bibr" rid="B158">2010</xref>).</p>
<p>Beta-catenin induces Per2 degradation altering circadian clock gene in intestinal mucosa of ApcMin/+ mice (Yang et al., <xref ref-type="bibr" rid="B209">2009</xref>). A decreased expression of Per1 and or Per2 has been reported in numerous cancers: breast cancer (Winter et al., <xref ref-type="bibr" rid="B198">2007</xref>), prostate cancer (Cao et al., <xref ref-type="bibr" rid="B15">2009</xref>), pancreatic cancer (Suzuki et al., <xref ref-type="bibr" rid="B179">2008</xref>), colorectal cancer (Mostafaie et al., <xref ref-type="bibr" rid="B122">2009</xref>), chronic myeloid leukemia (Yang et al., <xref ref-type="bibr" rid="B207">2011</xref>), gliomas (Fujioka et al., <xref ref-type="bibr" rid="B43">2006</xref>; Xia et al., <xref ref-type="bibr" rid="B202">2010</xref>), and intestinal epithelial neoplastic transformation (Yang et al., <xref ref-type="bibr" rid="B209">2009</xref>). Overexpression of Per1 and Per2 inhibits the growth of cancers cells (Gery et al., <xref ref-type="bibr" rid="B50">2006</xref>; Hua et al., <xref ref-type="bibr" rid="B70">2006</xref>) and increases apoptosis in tumor cells (Fu et al., <xref ref-type="bibr" rid="B42">2002</xref>; Gery et al., <xref ref-type="bibr" rid="B50">2006</xref>; Hua et al., <xref ref-type="bibr" rid="B70">2006</xref>; Sun et al., <xref ref-type="bibr" rid="B177">2010</xref>). Per1 and Per2 maintain the circadian rhythm of cells and sustain the normal cell cycle by regulating the expression of cell-related genes such as p53 and c-Myc (Duffield et al., <xref ref-type="bibr" rid="B38">2002</xref>; Fu et al., <xref ref-type="bibr" rid="B42">2002</xref>; Sancar et al., <xref ref-type="bibr" rid="B160">2004</xref>). In normal circumstances, the core circadian genes work in accurate feedback loops and keep the molecular clockworks in the SCN. They allow controlling peripheral clocks (Reppert and Weaver, <xref ref-type="bibr" rid="B147">2002</xref>; Schibler and Sassone-Corsi, <xref ref-type="bibr" rid="B166">2002</xref>). The levels of mRNAs and proteins of circadian genes oscillate throughout the 24 h period, exceptions of Clock (Reppert and Weaver, <xref ref-type="bibr" rid="B146">2001</xref>). Prevents studies have demonstrated the expression of mClock as a nuclear antigen in the SCN (Maywood et al., <xref ref-type="bibr" rid="B111">2003</xref>). Circadian clocks gene involves in gliomagenesis (Li et al., <xref ref-type="bibr" rid="B94">2013</xref>). The expression of Clock gene in the high-grade gliomas was found to be significantly higher than the low-grade gliomas and non-gliomas (Chen et al., <xref ref-type="bibr" rid="B24">2013</xref>). Clock gene is increased in grade III and IV glioma tissues cell lines (Li et al., <xref ref-type="bibr" rid="B94">2013</xref>). NF-kappaB activity is reduced and NF-KappaB target genes are repressed after Clock knockdown. An aberrant expression of Clock may disrupt the NF-kappaB pathway in glioma (Li et al., <xref ref-type="bibr" rid="B94">2013</xref>). Abnormalities in Per1 and Per2 expression are associated with the occurrence of gliomas (Xia et al., <xref ref-type="bibr" rid="B202">2010</xref>). Deregulation expression of c-Myc is suggested as a key factor leading to tumor development in Per2 mutant mice (Fu et al., <xref ref-type="bibr" rid="B42">2002</xref>). Overexpression of Per2 in irradiated glioma induces a decreased of c-Myc mRNA and protein levels (Gery et al., <xref ref-type="bibr" rid="B50">2006</xref>). The overexpression of Per2 induces Bmal1 expression and then increases intracellular levels of Bmal1/Clock proteins, in addition to repressing c-Myc (Fu et al., <xref ref-type="bibr" rid="B42">2002</xref>). The p53 protein binds the c-Myc promoter and represses it (Ho et al., <xref ref-type="bibr" rid="B68">2005</xref>). Overexpression of Per2 promotes apoptosis in glioma tissue by downregulating c-Myc and upregulating p53 (Zhanfeng et al., <xref ref-type="bibr" rid="B215">2015</xref>). Melatonin, which regulates circadian rhythms, has been demonstrated to significantly reduce damage-induced apoptosis in astrocytoma cells (Radogna et al., <xref ref-type="bibr" rid="B143">2009</xref>). Circadian genes may have a potential impact on glioma survival; genetic variation in the circadian pathway is associated with risk or outcome of glioma (Madden et al., <xref ref-type="bibr" rid="B106">2014</xref>).</p>
<p>PPAR interferes with the mammalian clock and energy metabolism (Chen and Yang, <xref ref-type="bibr" rid="B20">2014</xref>). PPARs are rhythmically expressed in mammalian tissues (Yang et al., <xref ref-type="bibr" rid="B208">2006</xref>), and directly interact with the core clock genes. PPAR gamma exhibits variations in diurnal expression in mouse fat, liver, and blood vessels (Yang et al., <xref ref-type="bibr" rid="B208">2006</xref>; Wang et al., <xref ref-type="bibr" rid="B195">2008</xref>). Deletion of PPAR gamma in mouse impairs diurnal rhythms (Yang G. et al., <xref ref-type="bibr" rid="B205">2012</xref>). PPAR gamma plays an important role in the coordinated control of circadian clocks, metabolism, and cardiac performance (Yang G. et al., <xref ref-type="bibr" rid="B205">2012</xref>). PGC-1 alpha, a transcriptional co-cativator that regulates energy metabolism, is rhythmically expressed in liver and skeletal muscle of mice. PGC-1 alpha upregulates the expression of clock genes Bmal1 and Rev-Erb alpha. Mice lacking PGC-1alpha show changes in CRs and metabolism (Liu et al., <xref ref-type="bibr" rid="B97">2007</xref>). PGC-1 alpha acts as a stress sensor in cancer cells. In maintaining metabolic homeostasis, PGC-1 alpha favors cancer cell survival and tumor metastasis (Tan et al., <xref ref-type="bibr" rid="B181">2016</xref>). PPAR gamma agonists activate Bmal1 and the formation of heterodimers Clock/Bmal1 (Wang et al., <xref ref-type="bibr" rid="B195">2008</xref>, <xref ref-type="bibr" rid="B193">2010</xref>). Curcumin activates Bmal1 through stimulation of PPAR gamma and could be a promising phytochemical treatment for gliomas (Sarma et al., <xref ref-type="bibr" rid="B162">2016</xref>).</p>
</sec>
<sec id="s12" sec-type="conclusions">
<title>Conclusion</title>
<p>Gliomas exhibit thermodynamic and metabolic alterations and abnormal circadian rhythms with an increasing entropy rate. In gliomas, the canonical WNT/beta-catenin pathway is upregulated, while PPAR gamma is downregulated. The two systems act in an opposite manner. Overactivation of the WNT pathway results in cell proliferation, due to the activation of target genes of beta-catenin, such as cyclin D1 and c-Myc. This activation of WNT pathway also promotes protein synthesis and angiogenesis. PDK and MCT-1 are also target genes of beta-catenin, explaining the decrease in the transformation of pyruvate into acetyl-CoA in mitochondria and the formation of intracellular lactate, which will be extruded out the cell. This is referred to as aerobic glycolysis or the Warburg effect. Circadian rhythms, dissipative structures, which are governed by the laws for far-from-equilibrium thermodynamics are disrupted in gliomas. They are influenced by both the WNT/beta-catenin pathway and PPAR gamma. Changes in thermodynamics, metabolism, and circadian rhythms are tightly linked in gliomas.</p>
</sec>
<sec id="s13">
<title>Author contributions</title>
<p>All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. The reviewer DJRL and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbot</surname><given-names>E. L.</given-names></name><name><surname>McCormack</surname><given-names>J. G.</given-names></name><name><surname>Reynet</surname><given-names>C.</given-names></name><name><surname>Hassall</surname><given-names>D. G.</given-names></name><name><surname>Buchan</surname><given-names>K. W. A. D.</given-names></name><name><surname>Yeaman</surname><given-names>S. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells</article-title>. <source/>FEBS J.
<volume>272</volume>, <fpage>3004</fpage>–<lpage>3014</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-4658.2005.04713.x</pub-id><pub-id pub-id-type="pmid">15955060</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>I.</given-names></name><name><surname>Aykin-Burns</surname><given-names>N.</given-names></name><name><surname>Sim</surname><given-names>J.</given-names></name><name><surname>Walsh</surname><given-names>S.</given-names></name><name><surname>Higashikubo</surname><given-names>R.</given-names></name><name><surname>Buettner</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Mitochondrial O<sub>2</sub> (center dot) and H<sub>2</sub>O<sub>2</sub> mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>4254</fpage>–<lpage>4263</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M411662200</pub-id><pub-id pub-id-type="pmid">15561720</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alao</surname><given-names>J. P.</given-names></name></person-group> (<year>2007</year>). <article-title>The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention</article-title>. <source/>Mol. Cancer
<volume>6</volume>:<fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-6-24</pub-id><pub-id pub-id-type="pmid">17407548</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angers</surname><given-names>S.</given-names></name><name><surname>Moon</surname><given-names>R. T.</given-names></name></person-group> (<year>2009</year>). <article-title>Proximal events in WNT signal transduction</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>10</volume>, <fpage>468</fpage>–<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2717</pub-id><pub-id pub-id-type="pmid">19536106</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumunk</surname><given-names>D.</given-names></name><name><surname>Reichelt</surname><given-names>U.</given-names></name><name><surname>Hildebrandt</surname><given-names>J.</given-names></name><name><surname>Krause</surname><given-names>H.</given-names></name><name><surname>Ebbing</surname><given-names>J.</given-names></name><name><surname>Cash</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC)</article-title>. <source/>World J. Urol.
<volume>31</volume>, <fpage>1191</fpage>–<lpage>1196</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-012-0874-5</pub-id><pub-id pub-id-type="pmid">22544372</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benadiba</surname><given-names>M.</given-names></name><name><surname>Dos Santos</surname><given-names>R. R.</given-names></name><name><surname>Silva Dde</surname><given-names>O.</given-names></name><name><surname>Colquhoun</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Inhibition of C6 rat glioma proliferation by [Ru2Cl(Ibp)4] depends on changes in p21, p27, Bax/Bcl2 ratio and mitochondrial membrane potential</article-title>. <source/>J. Inorg. Biochem.
<volume>104</volume>, <fpage>928</fpage>–<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2010.04.011</pub-id><pub-id pub-id-type="pmid">20605638</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>E.</given-names></name><name><surname>Vega</surname><given-names>N.</given-names></name><name><surname>Weiss-Gayet</surname><given-names>M.</given-names></name><name><surname>Géloën</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Gene network analysis of glucose liked signaling pathways and their role in human hepatocellular carcinoma cell growth and survival in HuH7 and HepG2 cell lines</article-title>. <source/>Biomed. Res. Int.
<volume>2015</volume>:<fpage>821761</fpage>. <pub-id pub-id-type="doi">10.1155/2015/821761</pub-id><pub-id pub-id-type="pmid">26380295</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bienz</surname><given-names>M.</given-names></name><name><surname>Clevers</surname><given-names>H.</given-names></name></person-group> (<year>2000</year>). <article-title>Linking colorectal cancer to WNT signaling</article-title>. <source/>Cell
<volume>103</volume>, <fpage>311</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="pmid">11057903</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouzier-Sore</surname><given-names>A. K.</given-names></name><name><surname>Canioni</surname><given-names>P.</given-names></name><name><surname>Merle</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Effect of exogenous lactate on rat glioma metabolism</article-title>. <source/>J. Neurosci. Res.
<volume>65</volume>, <fpage>543</fpage>–<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.1184</pub-id><pub-id pub-id-type="pmid">11550222</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabletz</surname><given-names>T.</given-names></name><name><surname>Hlubek</surname><given-names>F.</given-names></name><name><surname>Spaderna</surname><given-names>S.</given-names></name><name><surname>Schmalhofer</surname><given-names>O.</given-names></name><name><surname>Hiendlmeyer</surname><given-names>E.</given-names></name><name><surname>Jung</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin</article-title>. <source/>Cells Tissues Organs
<volume>179</volume>, <fpage>56</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1159/000084509</pub-id><pub-id pub-id-type="pmid">15942193</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braissant</surname><given-names>O.</given-names></name><name><surname>Foufelle</surname><given-names>F.</given-names></name><name><surname>Scotto</surname><given-names>C.</given-names></name></person-group> (<year>1996</year>). <article-title>Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat</article-title>. <source/>Endocrinology
<volume>137</volume>, <fpage>354</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1210/endo.137.1.8536636</pub-id><pub-id pub-id-type="pmid">8536636</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bright</surname><given-names>J. J.</given-names></name><name><surname>Kanakasabai</surname><given-names>S.</given-names></name><name><surname>Chearwae</surname><given-names>W.</given-names></name></person-group> (<year>2008</year>). <article-title>PPAR regulation of inflammatory signaling in CNS diseases</article-title>. <source/>PPAR Res.
<volume>2008</volume>:<fpage>658520</fpage>. <pub-id pub-id-type="doi">10.1155/2008/658520</pub-id><pub-id pub-id-type="pmid">18670616</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkart</surname><given-names>E. M.</given-names></name><name><surname>Sambandam</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name></person-group> (<year>2007</year>). <article-title>Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart</article-title>. <source/>J. Clin. Investig.
<volume>117</volume>, <fpage>3930</fpage>–<lpage>3939</lpage>. <pub-id pub-id-type="doi">10.1172/JCI32578</pub-id><pub-id pub-id-type="pmid">18037994</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canevari</surname><given-names>L.</given-names></name><name><surname>Abramov</surname><given-names>A. Y.</given-names></name><name><surname>Duchen</surname><given-names>M. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress</article-title>. <source/>Neurochem. Res.
<volume>29</volume>, <fpage>637</fpage>–<lpage>650</lpage>. <pub-id pub-id-type="pmid">15038611</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Gery</surname><given-names>S.</given-names></name><name><surname>Dashti</surname><given-names>A.</given-names></name><name><surname>Yin</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>A role for the clock gene per1 in prostate cancer</article-title>. <source/>Cancer Res.
<volume>69</volume>, <fpage>7619</fpage>–<lpage>7625</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4199</pub-id><pub-id pub-id-type="pmid">19752089</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Ouyang</surname><given-names>Q.</given-names></name><name><surname>Tu</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>The free energy cost of accurate biochemical oscillations</article-title>. <source/>Nat. Phys.
<volume>11</volume>, <fpage>772</fpage>–<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1038/nphys3412</pub-id><pub-id pub-id-type="pmid">26566392</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellone</surname><given-names>M. D.</given-names></name><name><surname>Teramoto</surname><given-names>H.</given-names></name><name><surname>Williams</surname><given-names>B. O.</given-names></name><name><surname>Druey</surname><given-names>K. M.</given-names></name><name><surname>Gutkind</surname><given-names>J. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis</article-title>. <source/>Science
<volume>310</volume>, <fpage>1504</fpage>–<lpage>1510</lpage>. <pub-id pub-id-type="doi">10.1126/science.1116221</pub-id><pub-id pub-id-type="pmid">16293724</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarti</surname><given-names>A.</given-names></name><name><surname>Dicker</surname><given-names>A.</given-names></name><name><surname>Mehta</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radio resistance in human gliomas: a review of preclinical and correlative clinical data</article-title>. <source/>Int. J. Radiat. Oncol. Biol. Phys.
<volume>58</volume>, <fpage>927</fpage>–<lpage>931</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijrobp.2003.09.092</pub-id><pub-id pub-id-type="pmid">14967452</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chearwae</surname><given-names>W.</given-names></name><name><surname>Bright</surname><given-names>J. J.</given-names></name></person-group> (<year>2008</year>). <article-title>PPAR gamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells</article-title>. <source/>Br. J. Cancer
<volume>99</volume>, <fpage>2044</fpage>–<lpage>2053</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6604786</pub-id><pub-id pub-id-type="pmid">19018263</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>PPARs Integrate the Mammalian Clock and Energy Metabolism</article-title>. <source/>PPAR Res.
<volume>2014</volume>:<fpage>653017</fpage>. <pub-id pub-id-type="doi">10.1155/2014/653017</pub-id><pub-id pub-id-type="pmid">24693278</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Pu</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>β-catenin/TCF4 complex transcriptionally regulates AKT1 in glioma</article-title>. <source/>Int. J. Oncol.
<volume>39</volume>, <fpage>883</fpage>–<lpage>890</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2011.1104</pub-id><pub-id pub-id-type="pmid">21720709</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Inhibition of growth and differentiation of osteo-progenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment</article-title>. <source/>Bone
<volume>35</volume>, <fpage>83</fpage>–<lpage>3595</lpage>. <pub-id pub-id-type="doi">10.1016/j.bone.2004.03.019</pub-id><pub-id pub-id-type="pmid">15207744</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y. C.</given-names></name><name><surname>Wu</surname><given-names>J. S.</given-names></name><name><surname>Tsai</surname><given-names>H. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders</article-title>. <source/>Mol. Neurobiol.
<volume>46</volume>, <fpage>114</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-012-8259-8</pub-id><pub-id pub-id-type="pmid">22434581</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>I.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Deregulated expression of the clock genes in gliomas</article-title>. <source/>Technol. Cancer Res. Treat.
<volume>12</volume>, <fpage>91</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.7785/tcrt.2012.500250</pub-id><pub-id pub-id-type="pmid">22905804</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>M. C.</given-names></name><name><surname>Chen</surname><given-names>C. M.</given-names></name><name><surname>Lee</surname><given-names>M. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma</article-title>. <source/>Hum. Mol. Genet.
<volume>19</volume>, <fpage>4043</fpage>–<lpage>4058</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq322</pub-id><pub-id pub-id-type="pmid">20668093</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>M. C.</given-names></name><name><surname>Cheng</surname><given-names>Y. C.</given-names></name><name><surname>Nicol</surname><given-names>C. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Rosiglitazone activation of PPARgamma-dependent signaling is neuroprotective in mutant huntingtin expressing cells</article-title>. <source/>Exp. Cell Res.
<volume>338</volume>, <fpage>183</fpage>–<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2015.09.005</pub-id><pub-id pub-id-type="pmid">26362846</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>W. T.</given-names></name><name><surname>Shen</surname><given-names>S. C.</given-names></name><name><surname>Chow</surname><given-names>J. M.</given-names></name><name><surname>Lin</surname><given-names>C. W.</given-names></name><name><surname>Shia</surname><given-names>L. T.</given-names></name><name><surname>Chen</surname><given-names>Y. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE (2) activation</article-title>. <source/>Neurobiol. Dis.
<volume>37</volume>, <fpage>118</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2009.09.015</pub-id><pub-id pub-id-type="pmid">19804834</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chocarro-Calvo</surname><given-names>A.</given-names></name><name><surname>Garcia-Martinez</surname><given-names>J. M.</given-names></name><name><surname>Ardila-Gonzalez</surname><given-names>S.</given-names></name><name><surname>De la Vieja</surname><given-names>A.</given-names></name><name><surname>Garcia-Jimenez</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Glucose-induced beta-catenin acetylation enhances WNT signaling in cancer</article-title>. <source/>Mol. Cell
<volume>49</volume>, <fpage>474</fpage>–<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2012.11.022</pub-id><pub-id pub-id-type="pmid">23273980</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisternas</surname><given-names>P.</given-names></name><name><surname>Salazar</surname><given-names>P.</given-names></name><name><surname>Silva-Alvarez</surname><given-names>C.</given-names></name><name><surname>Barros</surname><given-names>L. F.</given-names></name><name><surname>Inestrosa</surname><given-names>N. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Activation of WNT signaling in cortical neurons enhances glucose utilization through glycolysis</article-title>. <source/>J. Biol. Chem. <volume>291</volume>, <fpage>25950</fpage>–<lpage>25964</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.735373</pub-id><pub-id pub-id-type="pmid">27703002</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>WNT/beta-catenin signaling in development and disease</article-title>. <source/>Cell
<volume>127</volume>, <fpage>469</fpage>–<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2006.10.018</pub-id><pub-id pub-id-type="pmid">17081971</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H.</given-names></name><name><surname>Nusse</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>WNT/beta-catenin signaling and disease</article-title>. <source/>Cell
<volume>149</volume>, <fpage>1192</fpage>–<lpage>1205</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id><pub-id pub-id-type="pmid">22682243</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colca</surname><given-names>J. R.</given-names></name><name><surname>McDonald</surname><given-names>W. G.</given-names></name><name><surname>Cavey</surname><given-names>G. S.</given-names></name><name><surname>Holewa</surname><given-names>D. D.</given-names></name><name><surname>Brightwell-Conrad</surname><given-names>A. S.</given-names></name><name><surname>Wolfe</surname><given-names>C. L.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Identification of a mitochondrial target of thiazolidinediones insulin sensitizers (mTOT)-relationship to newy identified mitochondrial pyruvate carrier proteins</article-title>. <source/>PLoS ONE
<volume>8</volume>:<fpage>e61551</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0061551</pub-id><pub-id pub-id-type="pmid">23690925</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>J. T.</given-names></name></person-group> (<year>2007</year>). <article-title>What can a clock mutation in mice tell us about bipolar disorder?</article-title>
<source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>104</volume>, <fpage>6097</fpage>–<lpage>6098</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0701491104</pub-id><pub-id pub-id-type="pmid">17404212</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Berardinis</surname><given-names>R. J.</given-names></name><name><surname>Lum</surname><given-names>J. J.</given-names></name><name><surname>Hatzivassiliou</surname><given-names>G.</given-names></name><name><surname>Thompson</surname><given-names>C. B.</given-names></name></person-group> (<year>2008</year>). <article-title>The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</article-title>. <source/>Cell Metab.
<volume>7</volume>, <fpage>11</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id><pub-id pub-id-type="pmid">18177721</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denysenko</surname><given-names>T.</given-names></name><name><surname>Annovazzi</surname><given-names>L.</given-names></name><name><surname>Cassoni</surname><given-names>P.</given-names></name><name><surname>Melcarne</surname><given-names>A.</given-names></name><name><surname>Mellai</surname><given-names>M.</given-names></name><name><surname>Schiffer</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>WNT/β-catenin signaling pathway and downstream modulators in low- and high-grade glioma</article-title>. <source/>Cancer Genomics Proteomics<volume>13</volume>, <fpage>31</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="pmid">26708597</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desvergne</surname><given-names>B.</given-names></name><name><surname>Wahli</surname><given-names>W.</given-names></name></person-group> (<year>1999</year>). <article-title>Peroxisome proliferator-activated receptors: nuclear control of metabolism</article-title>. <source/>Endocr. Rev.
<volume>20</volume>, <fpage>649</fpage>–<lpage>688</lpage>. <pub-id pub-id-type="pmid">10529898</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djouadi</surname><given-names>F.</given-names></name><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name><name><surname>Hebert</surname><given-names>J. L.</given-names></name><name><surname>Charron</surname><given-names>P.</given-names></name><name><surname>Bastin</surname><given-names>J.</given-names></name><name><surname>Coirault</surname><given-names>C.</given-names></name></person-group> (<year>2009</year>). <article-title>A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy</article-title>. <source/>Cardiovasc. Res.
<volume>84</volume>, <fpage>83</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvp183</pub-id><pub-id pub-id-type="pmid">19497962</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffield</surname><given-names>G. E.</given-names></name><name><surname>Best</surname><given-names>J. D.</given-names></name><name><surname>Meurers</surname><given-names>B. H.</given-names></name><name><surname>Bittner</surname><given-names>A.</given-names></name><name><surname>Loros</surname><given-names>J. J.</given-names></name><name><surname>Dunlap</surname><given-names>J. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells</article-title>. <source/>Curr. Biol.
<volume>12</volume>, <fpage>551</fpage>–<lpage>557</lpage>. <pub-id pub-id-type="pmid">11937023</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbrecht</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Cullinan</surname><given-names>C. A.</given-names></name><name><surname>Hayes</surname><given-names>N.</given-names></name><name><surname>Leibowitz</surname><given-names>M.</given-names></name><name><surname>Moller</surname><given-names>D. E.</given-names></name><etal></etal></person-group>. (<year>1996</year>). <article-title>Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>224</volume>, <fpage>431</fpage>–<lpage>437</lpage>. <pub-id pub-id-type="pmid">8702406</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Auboeuf</surname><given-names>D.</given-names></name><name><surname>Raspe</surname><given-names>E.</given-names></name><name><surname>Schoonjans</surname><given-names>K.</given-names></name><name><surname>Lefebvre</surname><given-names>A. M.</given-names></name><name><surname>Saladin</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>The organization, promoter analysis, and expression of the human PPARgamma gene</article-title>. <source/>J. Biol. Chem.
<volume>272</volume>, <fpage>18779</fpage>–<lpage>18789</lpage>. <pub-id pub-id-type="pmid">9228052</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froberg</surname><given-names>M. K.</given-names></name><name><surname>Gerhart</surname><given-names>D. Z.</given-names></name><name><surname>Enerson</surname><given-names>B. E.</given-names></name><name><surname>Manivel</surname><given-names>C.</given-names></name><name><surname>Guzman-Paz</surname><given-names>M.</given-names></name><name><surname>Seacotte</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues</article-title>. <source/>Neuroreport
<volume>12</volume>, <fpage>761</fpage>–<lpage>765</lpage>. <pub-id pub-id-type="pmid">11277580</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>L.</given-names></name><name><surname>Pelicano</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <article-title>The circadian gene Period2 plays an important role in tumor suppression and DNA damage response <italic>in vivo</italic></article-title>. <source/>Cell
<volume>111</volume>, <fpage>41</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(02)00961-3</pub-id><pub-id pub-id-type="pmid">12372299</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujioka</surname><given-names>A.</given-names></name><name><surname>Takashima</surname><given-names>N.</given-names></name><name><surname>Shigeyoshi</surname><given-names>Y.</given-names></name></person-group> (<year>2006</year>). <article-title>Circadian rhythm generation in a glioma cell line</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>346</volume>, <fpage>169</fpage>–<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.094</pub-id><pub-id pub-id-type="pmid">16750513</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galeffi</surname><given-names>F.</given-names></name><name><surname>Turner</surname><given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Exploiting metabolic differences in glioma therapy</article-title>. <source/>Curr. Drug Technol.
<volume>9</volume>, <fpage>280</fpage>–<lpage>293</lpage>. <pub-id pub-id-type="doi">10.2174/157016312803305906</pub-id><pub-id pub-id-type="pmid">22339075</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>R.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Orfanelli</surname><given-names>U.</given-names></name><name><surname>Cipelletti</surname><given-names>B.</given-names></name><name><surname>Gritti</surname><given-names>A.</given-names></name><name><surname>De Vitis</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma</article-title>. <source/>Cancer Res.
<volume>64</volume>, <fpage>7011</fpage>–<lpage>7021</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1364</pub-id><pub-id pub-id-type="pmid">15466194</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Gras</surname><given-names>E.</given-names></name><name><surname>Lombardi</surname><given-names>R.</given-names></name><name><surname>Giocondo</surname><given-names>M. J.</given-names></name><name><surname>Willerson</surname><given-names>J. T.</given-names></name><name><surname>Schneider</surname><given-names>M. D.</given-names></name><name><surname>Khoury</surname><given-names>D. S.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Suppression of canonical WNT/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy</article-title>. <source/>J. Clin. Invest.
<volume>116</volume>, <fpage>2012</fpage>–<lpage>2021</lpage>. <pub-id pub-id-type="doi">10.1172/JCI27751</pub-id><pub-id pub-id-type="pmid">16823493</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>R. A.</given-names></name><name><surname>Gillies</surname><given-names>R. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Why do cancers have high aerobic glycolysis?</article-title>
<source/>Nat. Rev. Cancer
<volume>4</volume>, <fpage>891</fpage>–<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1478</pub-id><pub-id pub-id-type="pmid">15516961</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gekakis</surname><given-names>N.</given-names></name><name><surname>Staknis</surname><given-names>D.</given-names></name><name><surname>Nguyen</surname><given-names>H. B.</given-names></name><name><surname>Davis</surname><given-names>F. C.</given-names></name><name><surname>Wilsbacher</surname><given-names>L. D.</given-names></name><name><surname>King</surname><given-names>D. P.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Role of the CLOCK protein in the mammalian circadian mechanism</article-title>. <source/>Science
<volume>280</volume>, <fpage>1564</fpage>–<lpage>1569</lpage>. <pub-id pub-id-type="pmid">9616112</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhold</surname><given-names>D. L.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists</article-title>. <source/>Endocrinology
<volume>143</volume>, <fpage>2106</fpage>–<lpage>2118</lpage>. <pub-id pub-id-type="doi">10.1210/endo.143.6.8842</pub-id><pub-id pub-id-type="pmid">12021175</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gery</surname><given-names>S.</given-names></name><name><surname>Komatsu</surname><given-names>N.</given-names></name><name><surname>Baldjyan</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>A.</given-names></name><name><surname>Koo</surname><given-names>D.</given-names></name><name><surname>Koeffler</surname><given-names>H. P.</given-names></name></person-group> (<year>2006</year>). <article-title>The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells</article-title>. <source/>Mol. Cell
<volume>22</volume>, <fpage>375</fpage>–<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2006.03.038</pub-id><pub-id pub-id-type="pmid">16678109</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>R. J.</given-names></name><name><surname>Gatenby</surname><given-names>R. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Metabolism and its sequelae in cancer evolution and therapy</article-title>. <source/>Cancer J.
<volume>21</volume>, <fpage>88</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1097/PPO.0000000000000102</pub-id><pub-id pub-id-type="pmid">25815848</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girnun</surname><given-names>G. D.</given-names></name><name><surname>Domann</surname><given-names>F. E.</given-names></name><name><surname>Moore</surname><given-names>S. A.</given-names></name><name><surname>Robbins</surname><given-names>M. E.</given-names></name></person-group> (<year>2002</year>). <article-title>Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter</article-title>. <source/>Mol. Endocrinol.
<volume>16</volume>, <fpage>2793</fpage>–<lpage>2801</lpage>. <pub-id pub-id-type="doi">10.1210/me.2002-0020</pub-id><pub-id pub-id-type="pmid">12456800</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goessling</surname><given-names>W.</given-names></name><name><surname>North</surname><given-names>T. E.</given-names></name><name><surname>Loewer</surname><given-names>S.</given-names></name><name><surname>Lord</surname><given-names>A. M.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Stoick-Cooper</surname><given-names>C. L.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Genetic interaction of PGE2 and WNT signaling regulates developmental specification of stem cells and regeneration</article-title>. <source/>Cell
<volume>136</volume>, <fpage>1136</fpage>–<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.01.015</pub-id><pub-id pub-id-type="pmid">19303855</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeter</surname><given-names>A.</given-names></name></person-group> (<year>1973</year>). <article-title>Patterns of spatiotemporal organization in an allosteric enzyme model</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>70</volume>, <fpage>3255</fpage>–<lpage>3259</lpage>. <pub-id pub-id-type="pmid">4274133</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeter</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Computational approaches to cellular rhythms</article-title>. <source/>Nature
<volume>420</volume>, <fpage>238</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1038/nature01259</pub-id><pub-id pub-id-type="pmid">12432409</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>R. N.</given-names></name><name><surname>Colquhoun</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>E series prostaglandins alter the proliferative apoptotic and migratory properties of T98G human glioma cells <italic>in vitro</italic></article-title>. <source/>Lipids Health Dis.
<volume>11</volume>:<fpage>171</fpage>. <pub-id pub-id-type="doi">10.1186/1476-511X-11-171</pub-id><pub-id pub-id-type="pmid">23231886</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodenberger</surname><given-names>M. L.</given-names></name><name><surname>Jenkins</surname><given-names>R. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Genetics of adult glioma</article-title>. <source/>Cancer Genet.
<volume>205</volume>, <fpage>613</fpage>–<lpage>621</lpage>. <pub-id pub-id-type="doi">10.1016/j.cancergen.2012.10.009</pub-id><pub-id pub-id-type="pmid">23238284</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>B. C.</given-names></name></person-group> (<year>1965</year>). <article-title>Oscillatory behavior in enzymatic control processes</article-title>. <source/>Adv. Enzyme Regul.
<volume>3</volume>, <fpage>425</fpage>–<lpage>438</lpage>. <pub-id pub-id-type="pmid">5861813</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grommes</surname><given-names>C.</given-names></name><name><surname>Landreth</surname><given-names>G. E.</given-names></name><name><surname>Sastre</surname><given-names>M.</given-names></name><name><surname>Beck</surname><given-names>M.</given-names></name><name><surname>Feinstein</surname><given-names>D. L.</given-names></name><name><surname>Jacobs</surname><given-names>A. H.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Inhibition of <italic>in vivo</italic> glioma growth and invasion by peroxisome proliferator- activated receptor gamma agonist treatment</article-title>. <source/>Mol. Pharmacol.
<volume>70</volume>, <fpage>1524</fpage>–<lpage>1533</lpage>. <pub-id pub-id-type="doi">10.1124/mol.106.022194</pub-id><pub-id pub-id-type="pmid">16887936</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruetter</surname><given-names>R.</given-names></name></person-group> (<year>2003</year>). <article-title>Glycogen: the forgotten cerebral energy store</article-title>. <source/>J. Neurosci. Res.
<volume>74</volume>, <fpage>179</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.10785</pub-id><pub-id pub-id-type="pmid">14515346</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>B.</given-names></name><name><surname>Chatterjee</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>J. M.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Yechoor</surname><given-names>V. K.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The clock gene, brain and muscle Arnt-like 1, regulates adipogenesis via WNT signaling pathway</article-title>. <source/>Trends Cell Biol.
<volume>104</volume>, <fpage>508</fpage>–<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1096/fj.12-205781</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurpinar</surname><given-names>E.</given-names></name><name><surname>Grizzle</surname><given-names>W. E.</given-names></name><name><surname>Piazza</surname><given-names>G. A.</given-names></name></person-group> (<year>2014</year>). <article-title>NSAIDs inhibit tumorigenesis, but how?</article-title>
<source/>Clin. Cancer Res.
<volume>20</volume>, <fpage>1104</fpage>–<lpage>1113</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1573</pub-id><pub-id pub-id-type="pmid">24311630</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanselmann</surname><given-names>R. G.</given-names></name><name><surname>Welter</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Origin of cancer: an information, energy, and matter disease</article-title>. <source/>Front. Cell. Dev. Biol.
<volume>4</volume>:<fpage>121</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2016.00121</pub-id><pub-id pub-id-type="pmid">27909692</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardin</surname><given-names>P. E.</given-names></name><name><surname>Hall</surname><given-names>J. C.</given-names></name><name><surname>Rosbash</surname><given-names>M.</given-names></name></person-group> (<year>1990</year>). <article-title>Feedback of the Drosophila period gene product on circadian cycling of its messenger RNA levels</article-title>. <source/>Nature
<volume>343</volume>, <fpage>536</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="pmid">2105471</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazra</surname><given-names>S.</given-names></name><name><surname>Peebles</surname><given-names>K. A.</given-names></name><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Mao</surname><given-names>J. T.</given-names></name><name><surname>Dubinett</surname><given-names>S. M.</given-names></name></person-group> (<year>2008</year>). <article-title>The role of PPARgamma in the cyclooxygenase pathway in lung cancer</article-title>. <source/>PPAR Res.
<volume>2008</volume>:<fpage>790568</fpage>. <pub-id pub-id-type="doi">10.1155/2008/790568</pub-id><pub-id pub-id-type="pmid">18769553</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>T. C.</given-names></name><name><surname>Sparks</surname><given-names>A. B.</given-names></name><name><surname>Rago</surname><given-names>C.</given-names></name><name><surname>Hermeking</surname><given-names>H.</given-names></name><name><surname>Zawel</surname><given-names>L.</given-names></name><name><surname>da Costa</surname><given-names>L. T.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Identification of c-MYC as a target of the APC pathway</article-title>. <source/>Science
<volume>281</volume>, <fpage>1509</fpage>–<lpage>1512</lpage>. <pub-id pub-id-type="pmid">9727977</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helfer</surname><given-names>G.</given-names></name><name><surname>Tups</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Hypothalamic WNT signaling and its role in Energy Balance Regulation</article-title>. <source/>J. Neuroendocrinol.
<volume>28</volume>:<fpage>12368</fpage>
<pub-id pub-id-type="doi">10.1111/jne.12368</pub-id><pub-id pub-id-type="pmid">26802435</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>J. S.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Mao</surname><given-names>D. Y.</given-names></name><name><surname>Benchimol</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest</article-title>. <source/>Mol. Cell. Biol.
<volume>25</volume>, <fpage>7423</fpage>–<lpage>7431</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.25.17.7423-7431.2005</pub-id><pub-id pub-id-type="pmid">16107691</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogenesch</surname><given-names>J. B.</given-names></name><name><surname>Gu</surname><given-names>Y. Z.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Bradfield</surname><given-names>C. A.</given-names></name></person-group> (<year>1998</year>). <article-title>The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>95</volume>, <fpage>5474</fpage>–<lpage>5479</lpage>. <pub-id pub-id-type="pmid">9576906</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wan</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Circadian gene mPer2 overexpression induces cancer cell apoptosis</article-title>. <source/>Cancer Sci.
<volume>97</volume>, <fpage>589</fpage>–<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00225.x</pub-id><pub-id pub-id-type="pmid">16827798</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>T. K.</given-names></name><name><surname>Aslam</surname><given-names>R. S.</given-names></name><name><surname>Beckert</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>S.</given-names></name><name><surname>Ghani</surname><given-names>Q. P.</given-names></name><name><surname>Hussain</surname><given-names>M. Z.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms</article-title>. <source/>Antioxid. Redox Signal.
<volume>9</volume>, <fpage>1115</fpage>–<lpage>1124</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2007.1674</pub-id><pub-id pub-id-type="pmid">17567242</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janani</surname><given-names>C.</given-names></name><name><surname>Ranjitha Kumari</surname><given-names>B. D.</given-names></name></person-group> (<year>2015</year>). <article-title>PPAR gamma gene – a review</article-title>. <source/>Diabtes Metab. Syndr.
<volume>9</volume>, <fpage>46</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2014.09.015</pub-id><pub-id pub-id-type="pmid">25450819</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janich</surname><given-names>P.</given-names></name><name><surname>Pascual</surname><given-names>G.</given-names></name><name><surname>Merlos-Suarez</surname><given-names>A.</given-names></name><name><surname>Batlle</surname><given-names>E.</given-names></name><name><surname>Ripperger</surname><given-names>J.</given-names></name><name><surname>Albrecht</surname><given-names>U.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>The circadian molecular clock creates epidermal stem cell heterogeneity</article-title>. <source/>Nature
<volume>480</volume>, <fpage>209</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1038/nature10649</pub-id><pub-id pub-id-type="pmid">22080954</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>M. K.</given-names></name><name><surname>Suk</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas</article-title>. <source/>Brain Tumor Res. Treat.
<volume>1</volume>, <fpage>57</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.14791/btrt.2013.1.2.57</pub-id><pub-id pub-id-type="pmid">24904893</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fang</surname><given-names>B.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name></person-group> (<year>2011</year>). <article-title>Alpha-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of beta-catenin transactivation</article-title>. <source/>J. Neurooncol.
<volume>103</volume>, <fpage>445</fpage>–<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-010-0413-4</pub-id><pub-id pub-id-type="pmid">20872274</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway</article-title>. <source/>BMC Cancer.
<volume>12</volume>:<fpage>406</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-12-406</pub-id><pub-id pub-id-type="pmid">22967049</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahlert</surname><given-names>U. D.</given-names></name><name><surname>Maciaczyk</surname><given-names>D.</given-names></name><name><surname>Doostkam</surname><given-names>S.</given-names></name><name><surname>Orr</surname><given-names>B. A.</given-names></name><name><surname>Simons</surname><given-names>B.</given-names></name><name><surname>Bogiel</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Activation of canonical WNT/β-catenin signaling enhances <italic>in vitro</italic> motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition</article-title>. <source/>Cancer Lett.
<volume>325</volume>, <fpage>42</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2012.05.024</pub-id><pub-id pub-id-type="pmid">22652173</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>N.</given-names></name><name><surname>Chettiar</surname><given-names>S.</given-names></name><name><surname>Rathod</surname><given-names>S.</given-names></name><name><surname>Rath</surname><given-names>P.</given-names></name><name><surname>Muzumdar</surname><given-names>D.</given-names></name><name><surname>Shaikh</surname><given-names>M. L.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>WNT3a mediated activation of WNT/β-catenin signaling promotes tumor progression in glioblastoma</article-title>. <source/>Mol. Cell. Neurosci.
<volume>54</volume>, <fpage>44</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2013.01.001</pub-id><pub-id pub-id-type="pmid">23337036</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>M. M.</given-names></name><name><surname>Chi</surname><given-names>J. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Alternative fuels for cancer cells</article-title>. <source/>Cancer J.
<volume>21</volume>, <fpage>49</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1097/PPO.0000000000000104</pub-id><pub-id pub-id-type="pmid">25815843</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Gao</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y. C.</given-names></name><name><surname>Semenza</surname><given-names>G. L.</given-names></name><name><surname>Dang</surname><given-names>C. V.</given-names></name></person-group> (<year>2007</year>). <article-title>Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1</article-title>. <source/>Mol. Cell. Biol.
<volume>27</volume>, <fpage>7381</fpage>–<lpage>7393</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00440-07</pub-id><pub-id pub-id-type="pmid">17785433</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaus</surname><given-names>A.</given-names></name><name><surname>Birchmeier</surname><given-names>W.</given-names></name></person-group> (<year>2008</year>). <article-title>WNT signalling and its impact on development and cancer</article-title>. <source/>Nat. Rev. Cancer
<volume>8</volume>, <fpage>387</fpage>–<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2389</pub-id><pub-id pub-id-type="pmid">18432252</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>C. H.</given-names></name><name><surname>Takahashi</surname><given-names>J. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Molecular components of the mammalian circadian clock</article-title>. <source/>Hum. Mol. Genet.
<volume>2</volume>, <fpage>R271</fpage>–<lpage>R277</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddl207</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kondepudi</surname><given-names>D.</given-names></name><name><surname>Prigogine</surname><given-names>I.</given-names></name></person-group> (<year>1999</year>). <source/>Modern Thermodynamics from Heat Engines to Dissipative Structures. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Willey &amp; Sons</publisher-name>, <fpage>1</fpage>–<lpage>486</lpage>.</mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname><given-names>M. I.</given-names></name><name><surname>Giatromanolaki</surname><given-names>A.</given-names></name><name><surname>Harris</surname><given-names>A. L.</given-names></name><name><surname>Sivridis</surname><given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma</article-title>. <source/>Cancer Res.
<volume>66</volume>, <fpage>632</fpage>–<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3260</pub-id><pub-id pub-id-type="pmid">16423989</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavecchia</surname><given-names>A.</given-names></name><name><surname>Di Giovanni</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Amorfrutins are efficient modulators of peroxisome proliferator-activated receptor gamma (PPARγ) with potent antidiabetic and anticancer properties: a patent evaluation of WO2014177593 A1</article-title>. <source/>Expert Opin. Ther. Pat.
<volume>25</volume>, <fpage>1341</fpage>–<lpage>1347</lpage>. <pub-id pub-id-type="doi">10.1517/13543776.2015.1076393</pub-id><pub-id pub-id-type="pmid">26536161</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name><name><surname>Vallée</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Opposite interplay between PPAR gamma and canonical WNT/beta-catenin pathway in amyotrophic lateral sclerosis</article-title>. <source/>Front. Neurol.
<volume>7</volume>:<fpage>100</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2016.00100</pub-id><pub-id pub-id-type="pmid">27445967</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name><name><surname>Claes</surname><given-names>V.</given-names></name><name><surname>Hebert</surname><given-names>J. L.</given-names></name></person-group> (<year>2010</year>). <article-title>PPARs, cardiovascular metabolism, and function: near- or far-from-equilibrium pathways</article-title>. <source/>PPAR Res.
<volume>2010</volume>:<fpage>783273</fpage>. <pub-id pub-id-type="doi">10.1155/2010/783273</pub-id><pub-id pub-id-type="pmid">20706650</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name><name><surname>Claes</surname><given-names>V.</given-names></name><name><surname>Duthoit</surname><given-names>G.</given-names></name><name><surname>Hebert</surname><given-names>J. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Circadian rhythms, WNT/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction</article-title>. <source/>Front. Physiol.
<volume>5</volume>:<fpage>429</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00429</pub-id><pub-id pub-id-type="pmid">25414671</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name><name><surname>Krokidis</surname><given-names>X.</given-names></name><name><surname>Martin</surname><given-names>P.</given-names></name><name><surname>Pineau</surname><given-names>T.</given-names></name><name><surname>Hebert</surname><given-names>J. L.</given-names></name><name><surname>Quillard</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Increased entropy production in diaphragm muscle of PPAR alpha knockout mice</article-title>. <source/>J. Theor. Biol.
<volume>250</volume>, <fpage>92</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.106/j.jtbi.20007.09.022</pub-id><pub-id pub-id-type="pmid">17980390</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. C.</given-names></name><name><surname>Park</surname><given-names>I. C.</given-names></name><name><surname>Park</surname><given-names>M. J.</given-names></name><name><surname>An</surname><given-names>S.</given-names></name><name><surname>Woo</surname><given-names>S. H.</given-names></name><name><surname>Jin</surname><given-names>H. O.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2</article-title>. <source/>J. Cell. Biochem.
<volume>94</volume>, <fpage>597</fpage>–<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.20312</pub-id><pub-id pub-id-type="pmid">15546138</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>I. K.</given-names></name></person-group> (<year>2014</year>). <article-title>The role of pyruvate dehydrogenase kinase in diabetes and obesity</article-title>. <source/>Diabetes Metab. J.
<volume>38</volume>, <fpage>181</fpage>–<lpage>186</lpage>. <pub-id pub-id-type="doi">10.4093/dmj.2014.38.3.181</pub-id><pub-id pub-id-type="pmid">25003070</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>J. K.</given-names></name><name><surname>Ahn</surname><given-names>S. H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Nam</surname><given-names>D. H.</given-names></name></person-group> (<year>2016</year>). <article-title>WNT signaling in glioblastoma and therapeutic opportunities</article-title>. <source/>Lab. Invest.
<volume>96</volume>, <fpage>137</fpage>–<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.2015.140</pub-id><pub-id pub-id-type="pmid">26641068</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leushacke</surname><given-names>M.</given-names></name><name><surname>Barker</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>Lgr5 and Lgr6 as markers to study adult stem cell roles in self-renewal and cancer</article-title>. <source/>Oncogene
<volume>31</volume>, <fpage>3009</fpage>–<lpage>3022</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2011.479</pub-id><pub-id pub-id-type="pmid">22002312</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Tan</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Circadian gene Clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124</article-title>. <source/>FEBS Lett.
<volume>587</volume>, <fpage>2455</fpage>–<lpage>2460</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2013.06.018</pub-id><pub-id pub-id-type="pmid">23792158</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>H. T.</given-names></name><name><surname>Nellore</surname><given-names>A.</given-names></name><name><surname>Patsoukis</surname><given-names>N.</given-names></name><name><surname>Petkova</surname><given-names>V.</given-names></name><name><surname>McDonough</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Prostaglandin E2 promotes survival of naive UCB T cells via the WNT/beta-catenin pathway and alters immune reconstitution after UCBT</article-title>. <source/>Blood Cancer J.
<volume>4</volume>:<fpage>e178</fpage>. <pub-id pub-id-type="doi">10.1038/bcj.2013.75</pub-id><pub-id pub-id-type="pmid">24442207</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Tan</surname><given-names>Z.</given-names></name></person-group> (<year>2013</year>). <article-title>Over-expression of circadian clock gene Bmal1 affects proliferation and the canonical WNT pathway in NIH-3T3 cells</article-title>. <source/>Cell Biochem. Funct.
<volume>31</volume>, <fpage>166</fpage>–<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1002/cbf.2871</pub-id><pub-id pub-id-type="pmid">22961668</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Borjigin</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>J. D.</given-names></name></person-group> (<year>2007</year>). <article-title>Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism</article-title>. <source/>Nature
<volume>447</volume>, <fpage>477</fpage>–<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1038/nature05767</pub-id><pub-id pub-id-type="pmid">17476214</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Tu</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Bo</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>WNT/β-catenin pathway in human glioma: expression pattern and clinical/prognostic correlations</article-title>. <source/>Clin. Exp. Med.
<volume>11</volume>, <fpage>105</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1007/s10238-010-0110-9</pub-id><pub-id pub-id-type="pmid">20809334</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Zang</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Possinger</surname><given-names>K.</given-names></name><name><surname>Fan</surname><given-names>S.</given-names></name><name><surname>Elstner</surname><given-names>E.</given-names></name></person-group> (<year>2004</year>). <article-title>A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells</article-title>. <source/>Acta Pharmacol. Sin.
<volume>25</volume>, <fpage>1312</fpage>–<lpage>1319</lpage>. <pub-id pub-id-type="pmid">15456533</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zuo</surname><given-names>Y.</given-names></name><name><surname>Farmer</surname><given-names>S. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Functional interaction between peroxisome proliferator activated receptor gamma and beta-catenin</article-title>. <source/>Mol. Cell. Biol.
<volume>26</volume>, <fpage>5827</fpage>–<lpage>5837</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00441-06</pub-id><pub-id pub-id-type="pmid">16847334</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Ling</surname><given-names>F.</given-names></name></person-group> (<year>2011</year>). <article-title>β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastoma cells</article-title>. <source/>Med. Oncol.
<volume>28</volume>, <fpage>608</fpage>–<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1007/s12032-010-9476-5</pub-id><pub-id pub-id-type="pmid">20300972</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>D. N.</given-names></name></person-group> (<year>2006</year>). <article-title>Molecular pathology of malignant gliomas</article-title>. <source/>Annu. Rev. Pathol.
<volume>1</volume>, <fpage>97</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100043</pub-id><pub-id pub-id-type="pmid">18039109</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Carson</surname><given-names>D. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Repression of beta-catenin signaling by PPAR gamma ligands</article-title>. <source/>Eur. J. Pharmacol.
<volume>636</volume>, <fpage>198</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.03.010</pub-id><pub-id pub-id-type="pmid">20303941</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Forbes</surname><given-names>R. A.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>23111</fpage>–<lpage>23115</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M202487200</pub-id><pub-id pub-id-type="pmid">11943784</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lum</surname><given-names>J. J.</given-names></name><name><surname>Bui</surname><given-names>T.</given-names></name><name><surname>Gruber</surname><given-names>M.</given-names></name><name><surname>Gordan</surname><given-names>J. D.</given-names></name><name><surname>Be Berardinis</surname><given-names>R. J.</given-names></name><name><surname>Covello</surname><given-names>K. L.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis</article-title>. <source/>Genes Dev.
<volume>21</volume>, <fpage>1037</fpage>–<lpage>1049</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1529107</pub-id><pub-id pub-id-type="pmid">17437992</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madden</surname><given-names>M. H.</given-names></name><name><surname>Anic</surname><given-names>G. M.</given-names></name><name><surname>Thompson</surname><given-names>R. C.</given-names></name><name><surname>Nabors</surname><given-names>L. B.</given-names></name><name><surname>Olson</surname><given-names>J. J.</given-names></name><name><surname>Browning</surname><given-names>J. E.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Circadian pathway genes in relation to glioma risk and outcome</article-title>. <source/>Cancer Causes Control
<volume>25</volume>, <fpage>25</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1007/s10552-013-0305-y</pub-id><pub-id pub-id-type="pmid">24135790</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>T. J.</given-names></name><name><surname>Janssen</surname><given-names>A.</given-names></name><name><surname>Schmidt</surname><given-names>R.</given-names></name><name><surname>Geisslinger</surname><given-names>G.</given-names></name><name><surname>Grosch</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Targeting the betacatenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2- independent anticarcinogenic effects of celecoxib in human colon carcinoma cells</article-title>. <source/>FASEB J.
<volume>19</volume>, <fpage>1353</fpage>–<lpage>1355</lpage>. <pub-id pub-id-type="doi">10.1096/fj.04-3274fje</pub-id><pub-id pub-id-type="pmid">15946992</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamelak</surname><given-names>A. N.</given-names></name><name><surname>Jacoby</surname><given-names>D. B.</given-names></name></person-group> (<year>2007</year>). <article-title>Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601)</article-title>. <source/>Expert Opin. Drug Deliv.
<volume>4</volume>, <fpage>175</fpage>–<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1517/17425247.4.2.175</pub-id><pub-id pub-id-type="pmid">17335414</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>B. D.</given-names></name><name><surname>Cantley</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>AKT/PKB signaling: navigating downstream</article-title>. <source/>Cell
<volume>129</volume>, <fpage>1261</fpage>–<lpage>1274</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id><pub-id pub-id-type="pmid">17604717</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>G. D.</given-names></name><name><surname>Brucker</surname><given-names>D. P.</given-names></name><name><surname>Bahr</surname><given-names>O.</given-names></name><name><surname>Harter</surname><given-names>P. N.</given-names></name><name><surname>Hattingen</surname><given-names>E.</given-names></name><name><surname>Walenta</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy</article-title>. <source/>BMC Cancer
<volume>11</volume>:<fpage>315</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-11-315</pub-id><pub-id pub-id-type="pmid">21791085</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maywood</surname><given-names>E. S.</given-names></name><name><surname>O'Brien</surname><given-names>J. A.</given-names></name><name><surname>Hastings</surname><given-names>M. H.</given-names></name></person-group> (<year>2003</year>). <article-title>Expression of mCLOCK and other circadian clock-relevant proteins in the mouse suprachiasmatic nuclei</article-title>. <source/>J. Neuroendocrinol.
<volume>15</volume>, <fpage>329</fpage>–<lpage>334</lpage>. <pub-id pub-id-type="pmid">12622829</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFate</surname><given-names>T.</given-names></name><name><surname>Mohyeldin</surname><given-names>A.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Thakar</surname><given-names>J.</given-names></name><name><surname>Henriques</surname><given-names>J.</given-names></name><name><surname>Halim</surname><given-names>N. D.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells</article-title>. <source/>J. Biol. Chem.
<volume>283</volume>, <fpage>22700</fpage>–<lpage>22708</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M801765200</pub-id><pub-id pub-id-type="pmid">18541534</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellinghoff</surname><given-names>I. K.</given-names></name><name><surname>Wang</surname><given-names>M. Y.</given-names></name><name><surname>Vivanco</surname><given-names>I.</given-names></name><name><surname>Haas-Kogan</surname><given-names>D. A.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Dia</surname><given-names>E. Q.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors</article-title>. <source/>N. Engl. J. Med.
<volume>353</volume>, <fpage>2012</fpage>–<lpage>2024</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa051918</pub-id><pub-id pub-id-type="pmid">16282176</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>M.</given-names></name><name><surname>LaPointe</surname><given-names>M. C.</given-names></name></person-group> (<year>2003</year>). <article-title>PPAR gamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes</article-title>. <source/>Hypertension
<volume>42</volume>, <fpage>844</fpage>–<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1161/01.HYP.0000085332.69777.D1</pub-id><pub-id pub-id-type="pmid">12885795</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mineura</surname><given-names>K.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Kowada</surname><given-names>M.</given-names></name><name><surname>Shishido</surname><given-names>F.</given-names></name><name><surname>Ogawa</surname><given-names>T.</given-names></name><name><surname>Uemura</surname><given-names>K.</given-names></name></person-group> (<year>1986</year>). <article-title>Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose</article-title>. <source/>Neurol. Res.
<volume>8</volume>, <fpage>164</fpage>–<lpage>168</lpage>. <pub-id pub-id-type="pmid">2877410</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moldes</surname><given-names>M.</given-names></name><name><surname>Zuo</surname><given-names>Y.</given-names></name><name><surname>Morrison</surname><given-names>R. F.</given-names></name><name><surname>Silva</surname><given-names>D.</given-names></name><name><surname>Park</surname><given-names>B. H.</given-names></name><name><surname>Farmer</surname><given-names>S. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Peroxisome-proliferator-activated receptor gamma suppresses WNT/beta-catenin signalling during adipogenesis</article-title>. <source/>Biochem. J.
<volume>376</volume>, <fpage>607</fpage>–<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20030426</pub-id><pub-id pub-id-type="pmid">12954078</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>J. H.</given-names></name><name><surname>Kwon</surname><given-names>S.</given-names></name><name><surname>Jun</surname><given-names>E. K.</given-names></name><name><surname>Kim</surname><given-names>A.</given-names></name><name><surname>Whang</surname><given-names>K. Y.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Nanog-induced dedifferentiation of p53 deficient mouse astrocytes into brain cancer stem-like cells</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>412</volume>, <fpage>175</fpage>–<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2011.07.070</pub-id><pub-id pub-id-type="pmid">21810410</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>R. T.</given-names></name><name><surname>Bowerman</surname><given-names>B.</given-names></name><name><surname>Boutros</surname><given-names>M.</given-names></name><name><surname>Perrimon</surname><given-names>N.</given-names></name></person-group> (<year>2002</year>). <article-title>The promise and perils of WNT signaling through beta-catenin</article-title>. <source/>Science
<volume>296</volume>, <fpage>1644</fpage>–<lpage>1646</lpage>. <pub-id pub-id-type="doi">10.1126/science.1071549</pub-id><pub-id pub-id-type="pmid">12040179</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>R. T.</given-names></name><name><surname>Kohn</surname><given-names>A. D.</given-names></name><name><surname>De Ferrari</surname><given-names>G. V.</given-names></name><name><surname>Kaykas</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>WNT and beta-catenin signalling: diseases and therapies</article-title>. <source/>Nat. Rev. Genet.
<volume>5</volume>, <fpage>691</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1038/nrg1427</pub-id><pub-id pub-id-type="pmid">15372092</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor</surname><given-names>I.</given-names></name><name><surname>Cheung</surname><given-names>E. C.</given-names></name><name><surname>Vousden</surname><given-names>K. H.</given-names></name></person-group> (<year>2011</year>). <article-title>Control of glycolysis through regulation of PFK1: old friends and recent additions</article-title>. <source/>Cold Spring Harb. Symp. Quant. Biol.
<volume>76</volume>, <fpage>211</fpage>–<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1101/sqb.2011.76.010868</pub-id><pub-id pub-id-type="pmid">22096029</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morfouace</surname><given-names>M.</given-names></name><name><surname>Lalier</surname><given-names>L.</given-names></name><name><surname>Bahut</surname><given-names>M.</given-names></name><name><surname>Bonnamain</surname><given-names>V.</given-names></name><name><surname>Naveilhan</surname><given-names>P.</given-names></name><name><surname>Guette</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>33664</fpage>–<lpage>33674</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.320028</pub-id><pub-id pub-id-type="pmid">22782899</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafaie</surname><given-names>N.</given-names></name><name><surname>Kallay</surname><given-names>E.</given-names></name><name><surname>Sauerzapf</surname><given-names>E.</given-names></name><name><surname>Bonner</surname><given-names>E.</given-names></name><name><surname>Kriwanek</surname><given-names>S.</given-names></name><name><surname>Cross</surname><given-names>H. S.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer</article-title>. <source/>Mol. Carcinog.
<volume>48</volume>, <fpage>642</fpage>–<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1002/mc.20510</pub-id><pub-id pub-id-type="pmid">19148895</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname><given-names>C.</given-names></name><name><surname>Acebron</surname><given-names>S. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitotic and mitogenic WNT signalling</article-title>. <source/>EMBO J.
<volume>31</volume>, <fpage>2705</fpage>–<lpage>2713</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2012.124</pub-id><pub-id pub-id-type="pmid">22617425</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>WNT signaling in disease and in development</article-title>. <source/>Cell Res.
<volume>15</volume>, <fpage>28</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cr.7290260</pub-id><pub-id pub-id-type="pmid">15686623</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osthus</surname><given-names>R. C.</given-names></name><name><surname>Shim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Reddy</surname><given-names>R.</given-names></name><name><surname>Mukherjee</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc</article-title>. <source/>J. Biol. Chem.
<volume>275</volume>, <fpage>21797</fpage>–<lpage>21800</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.C000023200</pub-id><pub-id pub-id-type="pmid">10823814</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudard</surname><given-names>S.</given-names></name><name><surname>Arvelo</surname><given-names>F.</given-names></name><name><surname>Miccoli</surname><given-names>L.</given-names></name><name><surname>Apiou</surname><given-names>F.</given-names></name><name><surname>Dutrillaux</surname><given-names>A. M.</given-names></name><name><surname>Poisson</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1996</year>). <article-title>High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss</article-title>. <source/>Br. J. Cancer
<volume>74</volume>, <fpage>839</fpage>–<lpage>845</lpage>. <pub-id pub-id-type="pmid">8826847</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palos</surname><given-names>T. P.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Howard</surname><given-names>B. D.</given-names></name></person-group> (<year>1999</year>). <article-title>WNT signaling induces GLT-1 expression in rat glioma cells</article-title>. <source/>J. Neurchem.
<volume>73</volume>, <fpage>1012</fpage>–<lpage>1023</lpage>. <pub-id pub-id-type="pmid">10461890</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname><given-names>A.</given-names></name><name><surname>Tatenhorst</surname><given-names>L.</given-names></name><name><surname>Terwel</surname><given-names>D.</given-names></name><name><surname>Hermes</surname><given-names>M.</given-names></name><name><surname>Kummer</surname><given-names>M. P.</given-names></name><name><surname>Orlandi</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>PPAR gamma and RXR gamma ligands act synergistically as potent antineoplastic agents <italic>in vitro</italic> and <italic>in vivo</italic> glioma models</article-title>. <source/>J. Neurochem.
<volume>109</volume>, <fpage>1779</fpage>–<lpage>1790</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06111.x</pub-id><pub-id pub-id-type="pmid">19457135</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K.</given-names></name><name><surname>Lee</surname><given-names>R.</given-names></name><name><surname>Kang</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor gamma via the JNK-dependent pathway</article-title>. <source/>Exp. Cell Res.
<volume>297</volume>, <fpage>424</fpage>–<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2004.03.034</pub-id><pub-id pub-id-type="pmid">15212945</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pate</surname><given-names>K. T.</given-names></name><name><surname>Stringari</surname><given-names>C.</given-names></name><name><surname>Sprowl-Tanio</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>TeSlaa</surname><given-names>T.</given-names></name><name><surname>Hoverter</surname><given-names>N. P.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>WNT signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer</article-title>. <source/>EMBO J.
<volume>33</volume>, <fpage>1454</fpage>–<lpage>1473</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201488598</pub-id><pub-id pub-id-type="pmid">24825347</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>S. A.</given-names></name><name><surname>Hosni-Ahmed</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>T. S.</given-names></name><name><surname>Patil</surname><given-names>R.</given-names></name><name><surname>Pfeffer</surname><given-names>L. M.</given-names></name><name><surname>Miller</surname><given-names>D. D.</given-names></name></person-group> (<year>2013</year>). <article-title>Novel approaches to glioma drug design and drug screening</article-title>. <source/>Expert Opin. Drug Discov.
<volume>8</volume>, <fpage>1135</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1517/17460441.2013.807248</pub-id><pub-id pub-id-type="pmid">23738794</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paw</surname><given-names>I.</given-names></name><name><surname>Carpenter</surname><given-names>R. C.</given-names></name><name><surname>Watabe</surname><given-names>K.</given-names></name><name><surname>Debinski</surname><given-names>W.</given-names></name><name><surname>Lo</surname><given-names>H. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Mechanisms regulating glioma invasion</article-title>. <source/>Cancer Lett.
<volume>362</volume>, <fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2015.03.015</pub-id><pub-id pub-id-type="pmid">25796440</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>J. M.</given-names></name><name><surname>He</surname><given-names>X. C.</given-names></name><name><surname>Sugimura</surname><given-names>R.</given-names></name><name><surname>Grindley</surname><given-names>J. C.</given-names></name><name><surname>Haug</surname><given-names>J. S.</given-names></name><name><surname>Ding</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion</article-title>. <source/>Genes Dev.
<volume>25</volume>, <fpage>1928</fpage>–<lpage>1942</lpage>. <pub-id pub-id-type="doi">10.1101/gad.17421911</pub-id><pub-id pub-id-type="pmid">21890648</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>F.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>PPAR(gamma) and glucose homeostasis</article-title>. <source/>Annu. Rev. Nutr.
<volume>22</volume>, <fpage>167</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.nutr.22.010402.102808</pub-id><pub-id pub-id-type="pmid">12055342</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polakis</surname><given-names>P.</given-names></name></person-group> (<year>2012a</year>). <article-title>Drugging WNT signalling in cancer</article-title>. <source/>EMBO J.
<volume>31</volume>, <fpage>2737</fpage>–<lpage>2746</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2012.126</pub-id><pub-id pub-id-type="pmid">22617421</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polakis</surname><given-names>P.</given-names></name></person-group> (<year>2012b</year>). <article-title>WNT signaling in cancer</article-title>. <source/>Cold Spring Harb. Perspect. Biol.
<volume>31</volume>, <fpage>2737</fpage>–<lpage>2746</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2012.126</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>A. M.</given-names></name><name><surname>Purcaru</surname><given-names>S. O.</given-names></name><name><surname>Aleexandru</surname><given-names>O.</given-names></name><name><surname>Dricu</surname><given-names>O.</given-names></name></person-group> (<year>2016</year>). <article-title>New perspectives in glioblastoma antiangiogenic therapy</article-title>. <source/>Contemp. Oncol.
<volume>20</volume>, <fpage>109</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.5114/wo.2015.56122</pub-id><pub-id pub-id-type="pmid">27358588</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogine</surname><given-names>I.</given-names></name></person-group> (<year>1986</year>). <article-title>Life and physics. New perspectives</article-title>. <source/>Cell Biophys.
<volume>9</volume>, <fpage>217</fpage>–<lpage>224</lpage>. <pub-id pub-id-type="pmid">2436795</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogine</surname><given-names>I.</given-names></name><name><surname>Nicolis</surname><given-names>G.</given-names></name></person-group> (<year>1971</year>). <article-title>Biological order, structure and instabilities</article-title>. <source/>Q. Rev. Biophys.
<volume>4</volume>, <fpage>107</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="pmid">4257403</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogine</surname><given-names>I.</given-names></name><name><surname>Nicolis</surname><given-names>G.</given-names></name><name><surname>Babloyantz</surname><given-names>A.</given-names></name></person-group> (<year>1974</year>). <article-title>Nonequilibrium problems in biological phenomena</article-title>. <source/>Ann. N. Y. Acad. Sci.
<volume>231</volume>, <fpage>99</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="pmid">4522899</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Kang</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Downregulation of WNT2 and beta-catenin by siRNA suppresses malignant glioma cell growth</article-title>. <source/>Cancer Gene Ther.
<volume>16</volume>, <fpage>351</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1038/cgt.2008.78</pub-id><pub-id pub-id-type="pmid">18949017</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulvirenti</surname><given-names>T.</given-names></name><name><surname>Van Der Hejden</surname><given-names>M.</given-names></name><name><surname>Droms</surname><given-names>L. A.</given-names></name><name><surname>Huse</surname><given-names>J. T.</given-names></name><name><surname>Tabar</surname><given-names>V.</given-names></name><name><surname>Hall</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas</article-title>. <source/>Cancer Res.
<volume>71</volume>, <fpage>7280</fpage>–<lpage>7290</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1531</pub-id><pub-id pub-id-type="pmid">21990322</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radogna</surname><given-names>F.</given-names></name><name><surname>Nuccitelli</surname><given-names>S.</given-names></name><name><surname>Mengoni</surname><given-names>F.</given-names></name><name><surname>Ghibelli</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuroprotection by melatonin on astrocytoma cell death</article-title>. <source/>Ann. N. Y. Acad. Sci.
<volume>1171</volume>, <fpage>509</fpage>–<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04900.x</pub-id><pub-id pub-id-type="pmid">19723097</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>I.</given-names></name><name><surname>Thavathiru</surname><given-names>E.</given-names></name><name><surname>Ramalingam</surname><given-names>S.</given-names></name><name><surname>Natarajan</surname><given-names>G.</given-names></name><name><surname>Mills</surname><given-names>W. K.</given-names></name><name><surname>Benbrook</surname><given-names>D. M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>WNT inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis <italic>in vivo</italic></article-title>. <source/>Oncogene
<volume>31</volume>, <fpage>2725</fpage>–<lpage>2737</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2011.455</pub-id><pub-id pub-id-type="pmid">22002305</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangwala</surname><given-names>S. M.</given-names></name><name><surname>Lazar</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Peroxisome proliferator-activated receptor gamma in diabetes and metabolism</article-title>. <source/>Trends Pharmacol. Sci.
<volume>25</volume>, <fpage>331</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2004.03.012</pub-id><pub-id pub-id-type="pmid">15165749</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reppert</surname><given-names>S. M.</given-names></name><name><surname>Weaver</surname><given-names>D. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Molecular analysis of mammalian circadian rhythms</article-title>. <source/>Annu. Rev. Physiol.
<volume>63</volume>, <fpage>647</fpage>–<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.physiol.63.1.647</pub-id><pub-id pub-id-type="pmid">11181971</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reppert</surname><given-names>S. M.</given-names></name><name><surname>Weaver</surname><given-names>D. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Coordination of circadian timing in mammals</article-title>. <source/>Nature
<volume>418</volume>, <fpage>935</fpage>–<lpage>941</lpage>. <pub-id pub-id-type="doi">10.1038/nature00965</pub-id><pub-id pub-id-type="pmid">12198538</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>S. C.</given-names></name><name><surname>Chaturvedi</surname><given-names>M. M.</given-names></name><name><surname>Aggarwal</surname><given-names>B. B.</given-names></name></person-group> (<year>2010</year>). <article-title>Oxidative stress, inflammation, and cancer: how are they linked?</article-title>
<source/>Free Radic. Biol. Med.
<volume>49</volume>, <fpage>1603</fpage>–<lpage>1616</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.09.006</pub-id><pub-id pub-id-type="pmid">20840865</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>G.</given-names></name><name><surname>Benadiba</surname><given-names>M.</given-names></name><name><surname>Colquhoun</surname><given-names>A.</given-names></name><name><surname>Silva</surname><given-names>D. O.</given-names></name></person-group> (<year>2008</year>). <article-title>Diruthenium (II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: synthesis, characterization and their effects on tumour cell proliferation</article-title>. <source/>Polyhedron
<volume>27</volume>, <fpage>1131</fpage>–<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1016/j.poly.2007.12.011</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricard</surname><given-names>D.</given-names></name><name><surname>Idbaih</surname><given-names>A.</given-names></name><name><surname>Ducray</surname><given-names>F.</given-names></name><name><surname>Lahutte</surname><given-names>M.</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K.</given-names></name><name><surname>Delattre</surname><given-names>J. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Primary brain tumours in adults</article-title>. <source/>Lancet
<volume>379</volume>, <fpage>1984</fpage>–<lpage>1996</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)61346-9</pub-id><pub-id pub-id-type="pmid">22510398</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>P. L.</given-names></name><name><surname>Kelloff</surname><given-names>J.</given-names></name><name><surname>Sullivan</surname><given-names>H.</given-names></name><name><surname>Driggers</surname><given-names>L. J.</given-names></name><name><surname>Beard</surname><given-names>K. S.</given-names></name><name><surname>Kuwada</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Sulindac metabolites induce caspase- and proteasome-dependent degradation of betacatenin protein in human colon cancer cells</article-title>. <source/>Mol. Cancer Ther.
<volume>2</volume>, <fpage>885</fpage>–<lpage>892</lpage>. <pub-id pub-id-type="pmid">14555707</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riganti</surname><given-names>C.</given-names></name><name><surname>Salaroglio</surname><given-names>I. C.</given-names></name><name><surname>Caldera</surname><given-names>V.</given-names></name><name><surname>Campia</surname><given-names>I.</given-names></name><name><surname>Kopecka</surname><given-names>J.</given-names></name><name><surname>Melai</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Temozolomide down-regulates P-glycoprotein expression in glioblastoma stem cells by interfering with the WNT3a/glycogen synthase-3 kinase/β-catenin pathway</article-title>. <source/>Neuro Oncol.
<volume>15</volume>, <fpage>1502</fpage>–<lpage>1517</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/not104</pub-id><pub-id pub-id-type="pmid">23897632</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>T. E.</given-names></name><name><surname>Baker</surname><given-names>J. C.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Hiromasa</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms</article-title>. <source/>Prog. Nucleic Acid Res. Mol. Biol.
<volume>70</volume>, <fpage>33</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="pmid">11642366</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>M.</given-names></name><name><surname>Magnoni</surname><given-names>L.</given-names></name><name><surname>Miracco</surname><given-names>C.</given-names></name><name><surname>Mori</surname><given-names>E.</given-names></name><name><surname>Tosi</surname><given-names>P.</given-names></name><name><surname>Pirtoli</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Beta-catenin and Gli1 are prognostic markers in glioblastoma</article-title>. <source/>Cancer Biol. Ther.
<volume>11</volume>, <fpage>753</fpage>–<lpage>761</lpage>. <pub-id pub-id-type="pmid">21321483</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>W.</given-names></name><name><surname>Wild-Bode</surname><given-names>C.</given-names></name><name><surname>Platten</surname><given-names>M.</given-names></name><name><surname>Grimmel</surname><given-names>C.</given-names></name><name><surname>Melkonyan</surname><given-names>H. S.</given-names></name><name><surname>Dichgans</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells</article-title>. <source/>Oncogene
<volume>19</volume>, <fpage>4210</fpage>–<lpage>4220</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1203783</pub-id><pub-id pub-id-type="pmid">10980594</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouach</surname><given-names>N.</given-names></name><name><surname>Koulakoff</surname><given-names>A.</given-names></name><name><surname>Abudara</surname><given-names>V.</given-names></name><name><surname>Willecke</surname><given-names>K.</given-names></name><name><surname>Giaume</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>Astroglial metabolic networks sustain hippocampal synaptic transmission</article-title>. <source/>Science
<volume>322</volume>, <fpage>1551</fpage>–<lpage>1555</lpage>. <pub-id pub-id-type="doi">10.1126/science.1164022</pub-id><pub-id pub-id-type="pmid">19056987</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahar</surname><given-names>S.</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Metabolism and cancer: the circadian clock connection</article-title>. <source/>Nat. Rev. Cancer
<volume>9</volume>, <fpage>886</fpage>–<lpage>896</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2747</pub-id><pub-id pub-id-type="pmid">19935677</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahar</surname><given-names>S.</given-names></name><name><surname>Zocchi</surname><given-names>L.</given-names></name><name><surname>Kinoshita</surname><given-names>C.</given-names></name><name><surname>Borrelli</surname><given-names>E.</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Regulation of Bmal1 protein stability and circadian function by GSK3beta-mediated phosphorylation</article-title>. <source/>PLoS ONE
<volume>5</volume>:<fpage>e8561</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0008561</pub-id><pub-id pub-id-type="pmid">20049328</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sami</surname><given-names>A.</given-names></name><name><surname>Karsy</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding</article-title>. <source/>Tumour Biol.
<volume>34</volume>, <fpage>1991</fpage>–<lpage>2002</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-013-0800-5</pub-id><pub-id pub-id-type="pmid">23625692</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancar</surname><given-names>A.</given-names></name><name><surname>Lindsey-Boltz</surname><given-names>L. A.</given-names></name><name><surname>Ünsal-Kaçmaz</surname><given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints</article-title>. <source/>Annu. Rev. Biochem.
<volume>73</volume>, <fpage>39</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.biochem.73.011303.073723</pub-id><pub-id pub-id-type="pmid">15189136</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sareddy</surname><given-names>G. R.</given-names></name><name><surname>Panigrahi</surname><given-names>M.</given-names></name><name><surname>Challa</surname><given-names>S.</given-names></name><name><surname>Mahadevan</surname><given-names>A.</given-names></name><name><surname>Babu</surname><given-names>P. P.</given-names></name></person-group> (<year>2009</year>). <article-title>Activation of WNT/beta-catenin/Tcf signaling pathway in human astrocytomas</article-title>. <source/>Neurochem. Int.
<volume>55</volume>, <fpage>307</fpage>–<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2009.03.016</pub-id><pub-id pub-id-type="pmid">19576519</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarma</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>V. P.</given-names></name><name><surname>Sarka</surname><given-names>A. B.</given-names></name><name><surname>Sekar</surname><given-names>M. C.</given-names></name><name><surname>Samuel</surname><given-names>K.</given-names></name><name><surname>Geusz</surname><given-names>M. E.</given-names></name></person-group> (<year>2016</year>). <article-title>The circadian clock modulates anti-cancer properties of curcumin</article-title>. <source/>BMC Cancer
<volume>16</volume>:<fpage>759</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-016-2789-9</pub-id><pub-id pub-id-type="pmid">27680947</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>J.</given-names></name><name><surname>Kuroda</surname><given-names>Y.</given-names></name></person-group> (<year>2000</year>). <article-title>Beta-catenin expression in human neural cell lines following exposure to cytokines and growth factors</article-title>. <source/>Neuropathology
<volume>20</volume>, <fpage>113</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1046/j.1440-1789.2000.00293.x</pub-id><pub-id pub-id-type="pmid">10935448</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savvidis</surname><given-names>C.</given-names></name><name><surname>Koutsilieris</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Circadian rhythm disruption in cancer biology</article-title>. <source/>Mol. Med.
<volume>18</volume>, <fpage>1249</fpage>–<lpage>1260</lpage>. <pub-id pub-id-type="doi">10.2119/molmed.2012.00077</pub-id><pub-id pub-id-type="pmid">22811066</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepeler</surname><given-names>T.</given-names></name><name><surname>Holm</surname><given-names>A.</given-names></name><name><surname>Halvey</surname><given-names>P.</given-names></name><name><surname>Nordentoft</surname><given-names>I.</given-names></name><name><surname>Lamy</surname><given-names>P.</given-names></name><name><surname>Riising</surname><given-names>E. M.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes</article-title>. <source/>Oncogene
<volume>31</volume>, <fpage>2750</fpage>–<lpage>2760</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2011.453</pub-id><pub-id pub-id-type="pmid">21963845</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schibler</surname><given-names>U.</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>A web of circadian pacemakers</article-title>. <source/>Cell
<volume>111</volume>, <fpage>919</fpage>–<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(02)01225-4</pub-id><pub-id pub-id-type="pmid">12507418</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schule</surname><given-names>R.</given-names></name><name><surname>Dictus</surname><given-names>C.</given-names></name><name><surname>Campos</surname><given-names>B.</given-names></name><name><surname>Wan</surname><given-names>F.</given-names></name><name><surname>Felsberg</surname><given-names>J.</given-names></name><name><surname>Ahmadi</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Potential canonical WNT pathway activation in high-grade astrocytomas</article-title>. <source/>Sci. World J.
<volume>2012</volume>:<fpage>697313</fpage>. <pub-id pub-id-type="doi">10.1100/2012/697313</pub-id><pub-id pub-id-type="pmid">22919349</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seshacharyulu</surname><given-names>P.</given-names></name><name><surname>Ponnusamy</surname><given-names>M. P.</given-names></name><name><surname>Haridas</surname><given-names>D.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Ganti</surname><given-names>A.</given-names></name><name><surname>Batra</surname><given-names>S. K.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting the EGFR signaling pathway in cancer therapy</article-title>. <source/>Expert Opin. Ther. Targets
<volume>16</volume>, <fpage>15</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.2011.648617</pub-id><pub-id pub-id-type="pmid">22239438</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>C.</given-names></name><name><surname>Pradeep</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>L.</given-names></name><name><surname>Rana</surname><given-names>A.</given-names></name><name><surname>Rana</surname><given-names>B.</given-names></name></person-group> (<year>2004</year>). <article-title>Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>35583</fpage>–<lpage>35594</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M403143200</pub-id><pub-id pub-id-type="pmid">15190077</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Nuclear translocation of β-catenin is essential for glioma cell survival</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>7</volume>, <fpage>892</fpage>–<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9354-3</pub-id><pub-id pub-id-type="pmid">22415719</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shtutman</surname><given-names>M.</given-names></name><name><surname>Zhurinsky</surname><given-names>J.</given-names></name><name><surname>Simcha</surname><given-names>I.</given-names></name><name><surname>Albanese</surname><given-names>C.</given-names></name><name><surname>D'Amico</surname><given-names>M.</given-names></name><name><surname>Pestell</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>96</volume>, <fpage>5522</fpage>–<lpage>5527</lpage>. <pub-id pub-id-type="pmid">10318916</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siersbæk</surname><given-names>M. S.</given-names></name><name><surname>Loft</surname><given-names>A.</given-names></name><name><surname>Aagaard</surname><given-names>M. M.</given-names></name><name><surname>Nielsen</surname><given-names>R.</given-names></name><name><surname>Schmidt</surname><given-names>S. F.</given-names></name><name><surname>Petrovic</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Genome wide profiling of peroxisome proliferator-activated receptor g in primary epididymal, inguinal, and brown adipocytes reveals depot-selective binding correlated with gene expression</article-title>. <source/>Mol. Cell. Biol.
<volume>32</volume>, <fpage>3452</fpage>–<lpage>3463</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00526-12</pub-id><pub-id pub-id-type="pmid">22733994</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S. K.</given-names></name><name><surname>Hawkins</surname><given-names>C.</given-names></name><name><surname>Clarke</surname><given-names>I. D.</given-names></name><name><surname>Squire</surname><given-names>J. A.</given-names></name><name><surname>Bayani</surname><given-names>J.</given-names></name><name><surname>Hide</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Identification of human brain tumour initiating cells</article-title>. <source/>Nature
<volume>432</volume>, <fpage>396</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1038/nature03128</pub-id><pub-id pub-id-type="pmid">15549107</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soták</surname><given-names>M.</given-names></name><name><surname>Sumová</surname><given-names>A.</given-names></name><name><surname>Pácha</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Cross-talk between the circadian clock and the cell cycle in cancer</article-title>. <source/>Ann. Med.
<volume>46</volume>, <fpage>221</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.3109/07853890.2014.892296</pub-id><pub-id pub-id-type="pmid">24779962</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnolo</surname><given-names>A.</given-names></name><name><surname>Grant</surname><given-names>E. N.</given-names></name><name><surname>Glick</surname><given-names>R.</given-names></name><name><surname>Lichtor</surname><given-names>T.</given-names></name><name><surname>Feinstein</surname><given-names>D. L.</given-names></name></person-group> (<year>2007</year>). <article-title>Differential effects of PPAR gamma agonists on the metabolic properties of gliomas and astrocytes</article-title>. <source/>Neurosci. Lett.
<volume>417</volume>, <fpage>72</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2007.02.036</pub-id><pub-id pub-id-type="pmid">17324516</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suda</surname><given-names>T.</given-names></name><name><surname>Takudo</surname><given-names>K.</given-names></name><name><surname>Semenza</surname><given-names>G. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Metabolic regulation of hematopoietic stem cells in the hypoxic niche</article-title>. <source/>Cell Stem Cell
<volume>9</volume>, <fpage>298</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2011.09.010</pub-id><pub-id pub-id-type="pmid">21982230</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C. M.</given-names></name><name><surname>Huang</surname><given-names>S. F.</given-names></name><name><surname>Zeng</surname><given-names>J. M.</given-names></name><name><surname>Liu</surname><given-names>D. B.</given-names></name><name><surname>Xiao</surname><given-names>Q.</given-names></name><name><surname>Tian</surname><given-names>W. J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Per2 inhibits k562 leukemia cell growth <italic>in vitro</italic> and <italic>in vivo</italic> through cell cycle arrest and apoptosis induction</article-title>. <source/>Pathol. Oncol. Res.
<volume>16</volume>, <fpage>403</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1007/s12253-009-9227-0</pub-id><pub-id pub-id-type="pmid">19957060</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutendra</surname><given-names>G.</given-names></name><name><surname>Dromparis</surname><given-names>P.</given-names></name><name><surname>Kinnaird</surname><given-names>A.</given-names></name><name><surname>Stenson</surname><given-names>T. H.</given-names></name><name><surname>Haromy</surname><given-names>A.</given-names></name><name><surname>Parker</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer</article-title>. <source/>Oncogene
<volume>3</volume>, <fpage>1638</fpage>–<lpage>1650</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.198</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>F.</given-names></name><name><surname>Kondo</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Kusumi</surname><given-names>T.</given-names></name><name><surname>Fujimoto</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha. <italic>Biomed</italic></article-title>. <source/>Res.
<volume>29</volume>, <fpage>99</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.2220/biomedres.29.99</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>I.</given-names></name><name><surname>Kouzmenko</surname><given-names>A. P.</given-names></name><name><surname>Kato</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>WNT and PPARgamma signaling in osteoblastogenesis and adipogenesis</article-title>. <source/>Nat. Rev. Rheumatol.
<volume>5</volume>, <fpage>442</fpage>–<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2009.137</pub-id><pub-id pub-id-type="pmid">19581903</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Z.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Bode</surname><given-names>A. M.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>The role of PGC1alpha in cancer metabolism and its therapeutic implications</article-title>. <source/>Mol. Cancer Ther.
<volume>15</volume>, <fpage>774</fpage>–<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0621</pub-id><pub-id pub-id-type="pmid">27197257</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanase</surname><given-names>C. P.</given-names></name><name><surname>Enciu</surname><given-names>A. M.</given-names></name><name><surname>Mihai</surname><given-names>S.</given-names></name><name><surname>Neagu</surname><given-names>A. L.</given-names></name><name><surname>Calenic</surname><given-names>B.</given-names></name><name><surname>Cruceru</surname><given-names>N. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Anti-cancer therapies in high grade gliomas</article-title>. <source/>Curr. Proteomics
<volume>10</volume>, <fpage>246</fpage>–<lpage>260</lpage>. <pub-id pub-id-type="doi">10.2174/1570164611310030007</pub-id><pub-id pub-id-type="pmid">24228024</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>C. B.</given-names></name></person-group> (<year>2014</year>). <article-title>WNT meets Warburg: another piece in the puzzle?</article-title>
<source/>EMBO J.
<volume>33</volume>, <fpage>1420</fpage>–<lpage>1422</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201488785</pub-id><pub-id pub-id-type="pmid">24843042</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>W. J.</given-names></name><name><surname>Piazza</surname><given-names>G. A.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Fetter</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin</article-title>. <source/>Cancer Res.
<volume>60</volume>, <fpage>3338</fpage>–<lpage>3342</lpage>. <pub-id pub-id-type="pmid">10910034</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tinsley</surname><given-names>H. N.</given-names></name><name><surname>Gary</surname><given-names>B. D.</given-names></name><name><surname>Keeton</surname><given-names>A. B.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Piazza</surname><given-names>G. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic WNT/betacatenin- mediated transcription in human breast tumor cells</article-title>. <source/>Cancer Prev. Res.
<volume>4</volume>, <fpage>1275</fpage>–<lpage>1284</lpage>. <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-11-0095</pub-id><pub-id pub-id-type="pmid">21505183</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsacopoulos</surname><given-names>M.</given-names></name><name><surname>Magistretti</surname><given-names>P. J.</given-names></name></person-group> (<year>1996</year>). <article-title>Metabolic coupling between glia and neurons</article-title>. <source/>J. Neurosci.
<volume>16</volume>, <fpage>877</fpage>–<lpage>885</lpage>. <pub-id pub-id-type="pmid">8558256</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsuki</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Oka</surname><given-names>H.</given-names></name><name><surname>Tsuchiya</surname><given-names>B.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Fujii</surname><given-names>K.</given-names></name></person-group> (<year>2002</year>). <article-title>Relationship between the expression of E-, N-cadherins and β- catenin and tumor grade in astrocytomas</article-title>. <source/>J. Neurooncol.
<volume>57</volume>, <fpage>187</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="pmid">12125981</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallée</surname><given-names>A.</given-names></name><name><surname>Lecarpentier</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Alzheimer Disease: crosstalk between the canonical WNT/Beta- catenin pathway and PPARs alpha and gamma</article-title>. <source/>Front. Neurosci.
<volume>10</volume>:<fpage>459</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2016.00459</pub-id><pub-id pub-id-type="pmid">27807401</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>M. G.</given-names></name><name><surname>Cantley</surname><given-names>L. C.</given-names></name><name><surname>Thompson</surname><given-names>C. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source/>Science
<volume>324</volume>, <fpage>1029</fpage>–<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Shao</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>A.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Peroxisome proliferator- activated receptor g agonist pioglitazone inhibits b-catenin-mediated glioma cell growth and invasion</article-title>. <source/>Mol. Cell. Biochem.
<volume>349</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-010-0637-9</pub-id><pub-id pub-id-type="pmid">21221726</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2016</year>). <article-title>Centrosomal protein of 55 regulates glucose metabolism, proliferation and apoptosis of glioma cells via the Akt/mTOR signaling pathway</article-title>. <source/>J. Cancer
<volume>7</volume>, <fpage>1431</fpage>–<lpage>1440</lpage>. <pub-id pub-id-type="doi">10.7150/jca.15497</pub-id><pub-id pub-id-type="pmid">27471559</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Tony</surname><given-names>S. S.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy</article-title>. <source/>Arch. Biochem. Bipophys.
<volume>580</volume>, <fpage>84</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2015.07.005</pub-id><pub-id pub-id-type="pmid">26151775</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H. M.</given-names></name><name><surname>Zhao</surname><given-names>Y. X.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>G. D.</given-names></name><name><surname>Kang</surname><given-names>W. Y.</given-names></name><name><surname>Tang</surname><given-names>H. D.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>PPAR gamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes</article-title>. <source/>J. Alzheimers Dis.
<volume>20</volume>, <fpage>1189</fpage>–<lpage>1199</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2010-091336</pub-id><pub-id pub-id-type="pmid">20413894</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Circulating endothelial progenitor cells are involved in VEGFR-2-related endothelial differentiation in glioma</article-title>. <source/>Oncol. Rep.
<volume>32</volume>, <fpage>2007</fpage>–<lpage>2014</lpage>. <pub-id pub-id-type="doi">10.3892/or.2014.3467</pub-id><pub-id pub-id-type="pmid">25189411</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Aoyagi</surname><given-names>T.</given-names></name><name><surname>Soodvilai</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1</article-title>. <source/>Cell Metab.
<volume>8</volume>, <fpage>482</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2008.10.009</pub-id><pub-id pub-id-type="pmid">19041764</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O.</given-names></name></person-group> (<year>1956</year>). <article-title>On the origin of cancer cells</article-title>. <source/>Science
<volume>123</volume>, <fpage>309</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="pmid">13298683</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigfield</surname><given-names>S. M.</given-names></name><name><surname>Winter</surname><given-names>S. C.</given-names></name><name><surname>Giatromanolaki</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>J.</given-names></name><name><surname>Koukourakis</surname><given-names>M. L.</given-names></name><name><surname>Harris</surname><given-names>A. L.</given-names></name></person-group> (<year>2006</year>). <article-title>PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer</article-title>. <source/>Br. J. Cancer
<volume>98</volume>, <fpage>1975</fpage>–<lpage>1984</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6604356</pub-id><pub-id pub-id-type="pmid">18542064</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>S. L.</given-names></name><name><surname>Bosnoyan-Collins</surname><given-names>L.</given-names></name><name><surname>Pinnaduwage</surname><given-names>D.</given-names></name><name><surname>Andrulis</surname><given-names>I. L.</given-names></name></person-group> (<year>2007</year>). <article-title>Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors</article-title>. <source/>Neoplasia
<volume>9</volume>, <fpage>797</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="pmid">17971899</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>D. R.</given-names></name><name><surname>De Berardinis</surname><given-names>R. J.</given-names></name><name><surname>Mancuso</surname><given-names>A.</given-names></name><name><surname>Sayed</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>X. Y.</given-names></name><name><surname>Pfeiffer</surname><given-names>H. K.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>18782</fpage>–<lpage>18787</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0810199105</pub-id><pub-id pub-id-type="pmid">19033189</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C. T.</given-names></name><name><surname>Ahmad</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Crawford</surname><given-names>D. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Prostaglandin E2 alters WNT-dependent migration and proliferation in neuroectodermal stem cells: implications for autism spectrum disorders</article-title>. <source/>Cell Commun. Signal.
<volume>12</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/1478-811X-12-19</pub-id><pub-id pub-id-type="pmid">24656144</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>P. A.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Hrushesky</surname><given-names>W. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Clock genes and cancer</article-title>. <source/>Integr. Cancer Ther.
<volume>8</volume>, <fpage>303</fpage>–<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1177/1534735409355292</pub-id><pub-id pub-id-type="pmid">20042409</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H. C.</given-names></name><name><surname>Niu</surname><given-names>Z. F.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>S. Z.</given-names></name><name><surname>Hao</surname><given-names>S. C.</given-names></name><name><surname>Liu</surname><given-names>Z. T.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Deregulated expression of the Per1 and Per2 in human gliomas</article-title>. <source/>Can. J. Neurol. Sci.
<volume>37</volume>, <fpage>365</fpage>–<lpage>370</lpage>. <pub-id pub-id-type="pmid">20481271</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>VEGF promotes proliferation of human glioblastoma multiforme stem-like cells through VEGF receptor 2</article-title>. <source/>Sci. World J.
<volume>2013</volume>:<fpage>417413</fpage>. <pub-id pub-id-type="doi">10.1155/2013/417413</pub-id><pub-id pub-id-type="pmid">23533349</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Iyer</surname><given-names>R. R.</given-names></name><name><surname>Yu</surname><given-names>A. C.</given-names></name><name><surname>Yong</surname><given-names>R. L.</given-names></name><name><surname>Park</surname><given-names>D. M.</given-names></name><name><surname>Weil</surname><given-names>R. J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>6963</fpage>–<lpage>6968</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1118754109</pub-id><pub-id pub-id-type="pmid">22505738</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><name><surname>Aoyagi</surname><given-names>T.</given-names></name><name><surname>McClain</surname><given-names>D.</given-names></name><name><surname>Mortensen</surname><given-names>R. M.</given-names></name><name><surname>Yang</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Systemic PPARgamma deletion impairs circadian rhythms of behavior and metabolism</article-title>. <source/>PLoS ONE
<volume>7</volume>:<fpage>e38117</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0038117</pub-id><pub-id pub-id-type="pmid">22899986</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group> (<year>2016</year>). <article-title>SPOCK1 promotes the proliferation, migration and invasion of glioma cells through PI3K/AKT and Wnt/β-catenin signaling pathways</article-title>. <source/>Oncol. Rep.
<volume>35</volume>, <fpage>3566</fpage>–<lpage>3576</lpage>. <pub-id pub-id-type="doi">10.3892/or.2016.4757</pub-id><pub-id pub-id-type="pmid">27108836</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M. Y.</given-names></name><name><surname>Yang</surname><given-names>W. C.</given-names></name><name><surname>Lin</surname><given-names>P. M.</given-names></name><name><surname>Hsu</surname><given-names>J. F.</given-names></name><name><surname>Hsiao</surname><given-names>H. H.</given-names></name><name><surname>Liu</surname><given-names>Y. C.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Altered expression of circadian clock genes in human chronic myeloid leukemia</article-title>. <source/>J. Biol. Rhythms
<volume>26</volume>, <fpage>136</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.10785</pub-id><pub-id pub-id-type="pmid">21454294</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Downes</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>R. T.</given-names></name><name><surname>Bookout</surname><given-names>A. L.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Straume</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Nuclear receptor expression links the circadian clock to metabolism</article-title>. <source/>Cell
<volume>126</volume>, <fpage>801</fpage>–<lpage>810</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2006.06.050</pub-id><pub-id pub-id-type="pmid">16923398</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Wood</surname><given-names>P. A.</given-names></name><name><surname>Ansell</surname><given-names>C. M.</given-names></name><name><surname>Ohmori</surname><given-names>M.</given-names></name><name><surname>Oh</surname><given-names>E. Y.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Beta-catenin induces beta-TrCP mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice</article-title>. <source/>J. Biochem.
<volume>145</volume>, <fpage>289</fpage>–<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1093/jb/mvn167</pub-id><pub-id pub-id-type="pmid">19106159</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Downregulation of WIF-1 by hypermethylation in astrocytomas</article-title>. <source/>Acta Biochim. Biophys. Sin.
<volume>42</volume>, <fpage>418</fpage>–<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gmq037</pub-id><pub-id pub-id-type="pmid">20539942</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuniwa</surname><given-names>Y.</given-names></name><name><surname>Izumi</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>K. Y.</given-names></name><name><surname>Shimajiri</surname><given-names>S.</given-names></name><name><surname>Sasaguri</surname><given-names>Y.</given-names></name><name><surname>Kwai</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Circadian disruption accelerates tumor growth and angio/stromagenesis through a WNT signaling pathway</article-title>. <source/>PLoS ONE
<volume>5</volume>:<fpage>e15330</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0015330</pub-id><pub-id pub-id-type="pmid">21203463</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J. M.</given-names></name><name><surname>Jun</surname><given-names>E. S.</given-names></name><name><surname>Jung</surname><given-names>J. S.</given-names></name><name><surname>Suh</surname><given-names>S. Y.</given-names></name><name><surname>Han</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Role of WNT5a in the proliferation of human glioblastoma cells</article-title>. <source/>Cancer Lett.
<volume>257</volume>, <fpage>172</fpage>–<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2007.07.011</pub-id><pub-id pub-id-type="pmid">17709179</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>X.</given-names></name><name><surname>Lan</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Interruption of beta-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells</article-title>. <source/>Brain Res.
<volume>1366</volume>, <fpage>27</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2010.10.032</pub-id><pub-id pub-id-type="pmid">20969832</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>C.</given-names></name><name><surname>Wächter</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Posch</surname><given-names>M. G.</given-names></name><name><surname>Fenner</surname><given-names>M. H.</given-names></name><name><surname>Stadelmann</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Ligands for PPAR gamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas</article-title>. <source/>J. Neurooncol.
<volume>65</volume>, <fpage>7</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1023/B:NEON0000003728.80052.a8</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhanfeng</surname><given-names>N.</given-names></name><name><surname>Yanhiu</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Shaocai</surname><given-names>H.</given-names></name><name><surname>Guangxing</surname><given-names>L.</given-names></name><name><surname>Hechun</surname><given-names>X.</given-names></name></person-group> (<year>2015</year>). <article-title>Circadian genes Per1 ans Per2 increase rediosensitivity of glioma <italic>in vivo</italic></article-title>. <source/>Oncotarget
<volume>6</volume>, <fpage>9951</fpage>–<lpage>9958</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3179</pub-id><pub-id pub-id-type="pmid">25760074</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>Z.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>High beta-catenin/ Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression</article-title>. <source/>Neuro-oncology
<volume>13</volume>, <fpage>600</fpage>–<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nor034</pub-id><pub-id pub-id-type="pmid">21636708</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Pu</surname><given-names>P.</given-names></name><name><surname>Kang</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>WNT/beta-catenin signaling in glioma</article-title>. <source/>J. Neuroimmune Pharmacol.
<volume>7</volume>, <fpage>740</fpage>–<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9359-y</pub-id><pub-id pub-id-type="pmid">22454041</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Wei</surname><given-names>P.</given-names></name><name><surname>Gong</surname><given-names>A.</given-names></name><name><surname>Chiu</surname><given-names>W. T.</given-names></name><name><surname>Lee</surname><given-names>H. T.</given-names></name><name><surname>Colman</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>FoxM1 promotes β- catenin nuclear localization and controls WNT target-gene expression and glioma tumorigenesis</article-title>. <source/>Cancer Cell
<volume>20</volume>, <fpage>427</fpage>–<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2011.08.016</pub-id><pub-id pub-id-type="pmid">22014570</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Hulver</surname><given-names>M. W.</given-names></name><name><surname>McMillan</surname><given-names>R. P.</given-names></name><name><surname>Cline</surname><given-names>M. A.</given-names></name><name><surname>Gilbert</surname><given-names>E. R.</given-names></name></person-group> (<year>2014</year>). <article-title>The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility</article-title>. <source/>Nutr. Metab.
<volume>11</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/1743-7075-11-10</pub-id><pub-id pub-id-type="pmid">24520982</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z. Q.</given-names></name><name><surname>Chen</surname><given-names>H. Q.</given-names></name><name><surname>Chen</surname><given-names>Y. H.</given-names></name><name><surname>Cheng</surname><given-names>X. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Significance of β-catenin and cyclin D1 express in glioma</article-title>. <source/>Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
<volume>25</volume>, <fpage>1010</fpage>–<lpage>1012</lpage>. <pub-id pub-id-type="pmid">19900369</pub-id></mixed-citation>
</ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term>Acetytl-coA</term>
<def>
<p>Acetyl-coenzyme A</p>
</def>
</def-item>
<def-item>
<term>APC</term>
<def>
<p>Adenomatous polyposis coli</p>
</def>
</def-item>
<def-item>
<term>ARVC</term>
<def>
<p>Arrthymogenic right ventricular dysplasia/cardiomyopathy (ARVC)</p>
</def>
</def-item>
<def-item>
<term>Bmal1</term>
<def>
<p>Brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1</p>
</def>
</def-item>
<def-item>
<term>Clock</term>
<def>
<p>Circadian locomotor output cycles kaput</p>
</def>
</def-item>
<def-item>
<term>COX-2</term>
<def>
<p>Cyclooxygenase-2</p>
</def>
</def-item>
<def-item>
<term>Cry</term>
<def>
<p>Cryptochrome</p>
</def>
</def-item>
<def-item>
<term>Dsh</term>
<def>
<p>Disheveled</p>
</def>
</def-item>
<def-item>
<term>EMT</term>
<def>
<p>Epithelial-mesenchymal transition</p>
</def>
</def-item>
<def-item>
<term>Fzd</term>
<def>
<p>Frizzled</p>
</def>
</def-item>
<def-item>
<term>GK</term>
<def>
<p>Glucokinase</p>
</def>
</def-item>
<def-item>
<term>GLUT</term>
<def>
<p>Glucose transporter</p>
</def>
</def-item>
<def-item>
<term>GSK-3beta</term>
<def>
<p>Glycogen synthase kinase-3beta</p>
</def>
</def-item>
<def-item>
<term>HSC</term>
<def>
<p>Hematopoietic stem cell</p>
</def>
</def-item>
<def-item>
<term>LDH</term>
<def>
<p>Lactate dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>LRP 5/6</term>
<def>
<p>Low-density lipoprotein receptor-related protein 5/6</p>
</def>
</def-item>
<def-item>
<term>MCT-1</term>
<def>
<p>Monocarboxylate lactate transporter-</p>
</def>
</def-item>
<def-item>
<term>NSAID</term>
<def>
<p>Nonsteroidal anti-inflammatory drug</p>
</def>
</def-item>
<def-item>
<term>NDs</term>
<def>
<p>Neurodegenerative diseases</p>
</def>
</def-item>
<def-item>
<term>Per</term>
<def>
<p>Period</p>
</def>
</def-item>
<def-item>
<term>PPAR gamma</term>
<def>
<p>Peroxisome proliferator-activated receptor gamma</p>
</def>
</def-item>
<def-item>
<term>PGC-1alpha</term>
<def>
<p>Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha</p>
</def>
</def-item>
<def-item>
<term>PI3K-Akt</term>
<def>
<p>Phosphatidylinositol 3-kinase-protein kinase B</p>
</def>
</def-item>
<def-item>
<term>PFK-1</term>
<def>
<p>Phosphofructokinase-1</p>
</def>
</def-item>
<def-item>
<term>PGE2</term>
<def>
<p>Prostaglandin E2</p>
</def>
</def-item>
<def-item>
<term>PDH</term>
<def>
<p>Pyruvate dehydrogenase complex</p>
</def>
</def-item>
<def-item>
<term>PDK</term>
<def>
<p>Pyruvate dehydrogenase kinase</p>
</def>
</def-item>
<def-item>
<term>RTK</term>
<def>
<p>Receptor tyrosine kinase</p>
</def>
</def-item>
<def-item>
<term>TCF/LEF</term>
<def>
<p>T-cell factor/lymphoid enhancer factor</p>
</def>
</def-item>
<def-item>
<term>TZD</term>
<def>
<p>Thiazolidinedione</p>
</def>
</def-item>
<def-item>
<term>TCA</term>
<def>
<p>Tricarboxylic acid.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>